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Abstract 
 
Current progress in the development of vaccines has decreased 
the incidence of fatal and non-fatal infections and increased longevity.  
However, new technologies need to be developed to combat an 
emerging generation of infectious diseases.  DNA vaccination has been 
demonstrated to have great potential for use against a wide variety of 
diseases.  Alone, this vaccine technology does not generate a 
significant immune response for vaccination, but combined with 
delivery by electroporation (EP), can enhance plasmid expression and 
immunity against the expressed antigen.  Most EP systems, while 
effective, can be invasive and painful making them less desirable for 
use in vaccination.  Our lab recently developed a non-invasive 
electrode known as the multi-electrode array (MEA), which lies flat on 
the surface of the skin without penetrating the tissue.   This study 
evaluated the use of the MEA for the development of DNA vaccines.  
We assessed the appropriate delivery conditions for gene expression 
and the development of humoral immunity.  We used both B. anthracis 
and HBV as infectious models for our experiments.  Our results 
indicated that the MEA can enhance gene expression in a mouse model 
xii 
 
with minimal to no tissue damage.  Optimal delivery conditions, based 
on generation of antibodies, were determined to be 125-175V/cm and 
150ms with 200ug and a prime boost protocol administered on Day 0 
and 14.  Under these conditions, end-point titers of 20,000-25,000 
were generated.  Neutralizing antibodies were noted in 40-60% of 
animals.  
Additionally, we utilized a guinea pig model to assess the 
translation potential of this electrode.  The plasmid encoding HBsAg, 
pHBsAg, was delivered intradermally with the MEA to guinea pig skin.  
The results show increased protein expression resulting from plasmid 
delivery using the MEA as compared to injection alone.  Within 48 
hours of treatment, there was an influx of cellular infiltrate in the 
experimental groups.  Humoral responses were also increased 
significantly in both duration and intensity as compared to the injection 
only groups.  Results from both experimental models demonstrate that 
protective levels of humoral immunity can be generated and that this 
electrode should translate well to the clinic. 
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Introduction 
Vaccine Development - history 
The development of vaccines is arguably one of the most 
important medical advancements of the 20th century.  However, 
humans have been attempting passive protection from disease since 
500BC.  The Chinese developed the first passive vaccines and since 
then our knowledge base has grown to allow us to develop more 
sophisticated technologies for fighting infectious disease. From the 
“black plague,” to diseases like small pox, whooping cough, 
tuberculosis, measles, and influenza which at times decimated much of 
the world's population.  The intentional development of vaccines 
became a reality when it was noted that milk maids exposed to 
cowpox did not become sick from small pox.  This was the first modern 
recognition that passive protection from disease could be achieved and 
intentionally transferred.  Prior to that Robert Koch developed his 
postulates based on the findings and identification of anthrax. 
 This led to a whole new era of vaccine development.  The advent 
of the US Centers for Disease Control and Prevention was in direct 
response to help citizens understand their role in preventing disease.  
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Mass communications on posters and radio spread messages to keep 
your hands clean and stay indoors when sick.  The mid-20th century 
gave rise to advancements in the area of bacteriology and infection 
disease.  Additionally, the development technologies that would allow 
us to better diagnose and combat infectious diseases spurred 
advancements of vaccines against common agents like measles, 
mumps, and rubella, and whooping cough.  Several of these vaccines 
were made mandatory by the US government to prevent further 
fatalities and spreading of the infections.  The limitation that science is 
continually faced with is emerging infections where traditional methods 
of vaccinations have been unsuccessful.  Development of vaccines has 
since sputtered but several methods have been developed that show 
promise for continued use against emerging infections   
DNA Vaccines 
DNA vaccines are genetically engineered plasmid DNA that 
encode for antigenic proteins under the control of a eukaryotic 
promoter.  The most important parts of the plasmid are the promoter 
(most commonly CMV, RSV, SV40, and LTR used to drive constant 
stable expression in mammalian cells), the transgene (the gene of 
interest for vaccination), and the polyadenlyation sequence 
(responsible for mRNA stability and translation).  The basic mechanism 
of DNA vaccination is that the DNA is injected into the tissue (muscle, 
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skin, subcutaneous space, etc) and enters the host cell.  The DNA is 
translocated to the nucleus where transcription and translation occur 
to generate the target protein.  The peptides are then presented on 
the cell surface by MHC I, or secreted (depending on the construction 
of the plasmid).  The presented protein is then picked up and 
undergoes immune stimulation by APCs [2]. 
 There are several advantages to using DNA vaccines over more 
traditional vaccination methods.  First, DNA is highly stable, relatively 
easily produced, and stored [3-5].  Secondly, DNA vaccines can induce 
humoral and cellular immunity like live attenuated vaccines without 
the risk of reversion [6, 7].  Third, they have been demonstrated to 
have fewer side effects.  Fourth, DNA vaccines can be multivalent, 
expressing multiple antigenic components on a single vaccine which 
could be useful for vaccinating against multiple agents simultaneously 
or agents multiple subunits of the same antigen [3-5].  Finally the use 
of DNA vaccines prevents the need for cold chain storage of vaccines 
during transport.   
 Initial studies into DNA vaccination began in the early 90’s when 
Wolf et al demonstrated that DNA could be taken up by muscle cells 
and that integration into mouse genomic DNA did not occur [8].  These 
data opened up a whole new world for DNA vaccines to take off.  
Shortly thereafter several studies were conducted evaluating the 
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development of immunity from DNA vaccination.  It was reported that 
mice injected with Influenza DNA encoding for the highly conserved 
nucleoprotein were protected from lethal challenge [9].  In this study 
both induction of humoral and cell mediated immunity was noted 
though protection was correlated to CMI.  Since this study, several 
infectious agents have been tested for development of vaccination 
(Table 1).  Many of these studies have been focused on viral 
pathogens like: HIV, HBV, HSV, LCMV and Rabies Virus.  The use of 
DNA vaccination has also been evaluated for the development of 
immunity against parasitic infections like: Plasmodium falciparum and 
Leishmania donovani; as well as bacterial pathogens like: 
Mycobacterium tuberculosis and Clostridium tetani.   
 A variety of animal models have also been utilized to study DNA 
vaccination and the subsequent development of immunity.  The most 
common has been the mouse model where initial studies were 
conducted as described earlier, but also continues to be the most 
common model for ease of use and reagent availability.  However, 
several other models have been used including: cattle, rabbits, dogs, 
rats, guinea pigs, and NHP’s with varying degrees of success.   
 Delivery of DNA is an important consideration development of 
immunity.  The primary injection site for DNA vaccination has been 
muscle.  This is primarily because early studies demonstrated that 
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direct injection into the muscle was superior to other tissue types [10] 
and that it was superior to adenoviral vectors [11].  This is most likely 
due to the long turnover of myocytes and their post mitotic state [12].  
Despite the success of these results the preclinical models did not line 
up with initial human clinical trials [13].  For DNA vaccination to 
become a reality improved delivery systems were necessary to 
develop. 
 
Viruses Bacteria Parasites 
HIV [121, 122] Borrellia burgdorferi 
[123, 124] 
Plasmodium 
falciparum [125] 
SARS [126-128] Clostridium tetani 
[129] 
Leishmania major/ 
donovani [130-132] 
Influenza[133-135] Mycobacterium 
tuberculosis [136-
140] 
Toxoplasma gondii 
[141-146] 
Rabies Virus[147, 
148] 
Bacillus anthracis 
[149, 150] 
Tania Ovis [151] 
HBV [152-154] Clostridium 
botulinum [155, 
156] 
Schistosoma mansoni 
[157, 158] 
HCV [159, 160]   
Ebola Virus [161]   
HSV[162, 163]   
HPV [164]   
WNV [165]   
Rotavirus [166, 167]   
St. Louis 
Encephalitis Virus 
[168] 
  
 
 
 
Table 1. DNA vaccines against infectious agents.   
*Pubmed keywords:  DNA vaccine, Infectious disease 
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Electroporation 
 EP requires the application of electric fields causing 
permeabilization of the cell membranes [14, 15].  While there is still 
much unknown about the exact mechanisms of DNA entry into cell, 
what is understood is that it is a complex process involving interaction 
of the DNA with the cell membrane and that the DNA makes its way to 
the nucleus once inside the cell where it undergoes transcription and 
translation.  At the time of EP pulsing, the DNA may be taken up by 
several processes, but one idea is that small “pores” are created in the 
membrane [15].  These holes are transient and are resolved very 
quickly; therefore, the DNA must be present at the time of pulsing.  
The resolution of the membrane pores allows the cell to continue to 
undergo normal cell function and processing including 
transcription/translation of the DNA.   
Initial studies evaluating in vivo EP for transgene delivery and 
expression were performed on rat brain tumors [16] and rat livers 
[17].  Those studies demonstrated enhanced delivery and expression 
of plasmid DNA from EP mediated delivery.  Further experimentation 
revealed that transgene expression could be increased 100-1000 fold 
from muscle EP stimulation [18-20].  Similar fold enhancements have 
also been seen in skin tissues ranging from 10-1000 fold [1].  
Successful EP mediated DNA delivery has been demonstrated in most 
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tissue types and for several therapeutic and prophylactic indications 
such as cancer therapy, infectious diseases, wound healing, metabolic 
disorders and vaccines [21].  Recently several US clinical trials have 
been initiated.  Eight clinical trials have been completed using EP, 
three assessing EP devices for use against infectious agents.  21 
others are currently active or recruiting.  12 of those are involving DNA 
vaccination against infectious agents (clinicaltrials.gov; Keyword:  
Electroporation).   
Electrically enhanced DNA vaccinations 
Initial in vivo EP DNA vaccine studies evaluated gene expression 
and immune stimulation from delivery of plasmids encoding either HBV 
protein or HIV protein, gag, to the muscle.  Their results confirmed 
that increased humoral responses to HBV [22] and cellular [23] 
immune response to HIV gag from EP compared to injection only (IO) 
of plasmid DNA.  More recent studies have broadened the list of 
pathogens which EP has been successfully used in vivo to include other 
viral pathogens such as: HIV [24-27], SARS-CoV [28, 29], Influenza 
[30-34], WNV and JEV [35, 36], as well as HBV, HCV [37-41] and HPV 
[42, 43].  EP delivered DNA vaccines expressing proteins of the 
parasitic infection Plasmodium falciparum, one of the parasites causing 
malaria [44], as well as bacterial infections like Bacillus anthracis [45], 
8 
 
Clostridium botulinum [46], and Mycobacterium tuberculosis [47] have 
also been demonstrated to enhance immunogenicity.  These results 
demonstrate the capacity of EP to enhance not only gene delivery and 
protein expression but also its ability to stimulate the host immune 
response against a wide variety of pathogens. 
Target tissues for electrically mediated DNA Vaccine delivery 
Currently, electrically mediated delivery of DNA vaccines 
typically employ painful invasive needle electrodes that are inserted 
into the muscle for electrical stimulation.  The primary tissue used for 
in vivo EP is muscle because it is accessible, highly vascularized, 
multinucleated, and expresses DNA for long periods of time due to the 
post-mitotic nature of the tissue [12].  However, pain associated with 
administration is not desirable.  As such, alternative delivery sites and 
methods have been explored.  The skin is an attractive target for 
vaccination because of the high proportion of APC’s and a large surface 
area.  Recent studies, as well as work done in our laboratory, 
demonstrated that intradermal electrically mediated DNA expression 
can be increased both locally and systemically [48-53].  Electrodes 
developed for skin EP include: caliper, plate, tweezer, and clip 
electrodes as well as several needle electrodes [54-58]. 
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Table 2. In vivo Electrically Mediated DNA 
vaccines against infectious 
   
*Pubmed keywords:  Electroporation and DNA vaccine or 
Electrically Mediated DNA vaccine. 
 
 
 
 
 
The skin as a target for delivery 
The skin is a highly complex and immunogenic organ.  It is the 
largest organ in the body, and well equipped for recognizing and 
defending against infection.  Its primary functions are to defend 
against infection and insulate and regulate temperature as well as 
regulating absorption and fluid loss and sensation.  Human skin varies 
in thickness from about 0.5mm on the eyelids to 4mm on the hands 
and soles of the feet, with the majority of skin being between 1 and 
2mm.  The skin structure is made up of three layers:  the epidermis, 
the dermis, and the subcutaneous layers.  The epidermis consists 
primarily of keratinocytes, but also contains melanocytes and 
epidermal dendritic cells known as langerhans cells.  It is made up of 
HIV/ SIV [23-27] 
SARS [28, 29] 
Influenza [30-34] 
WNV [35] 
JEV [36] 
HBV and HCV [37-41] 
HPV [42, 43] 
Plasmodium falciparum [44] 
Bacillus anthracis [45] 
Clostridium botulinum [46]  
Mycobacterium tuberculosis 
[47] 
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five strata:  stratum corneum, lucidum, granulosum, spinosum, 
basale.  Cells are formed at the basale membrane and migrate up the 
strata changing shape and composition until they reach the stratum 
corneum where they are sloughed off.  The rate of turnover is 
approximately 27 days [59]. The dermis, the main candidate for 
injection of DNA in the skin, consists of fibroblasts and dermal 
dendritic cells (highly efficient antigen presenting cells).  In this layer, 
the hair follicles, sweat glands and blood vessels are found.  The 
subcutaneous layer consists of connective tissue and fat.  The primary 
cell types are fibroblasts, macrophages and fat cells [60].    
11 
 
 
  
Figure 1. Human Skin Structure.  Cartoon image of human 
skin, showing epidermis, dermis and subcutaneous layer.  
Also represented are hair follicles and the basement 
membrane.  Image from www.skininfo.org. 
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Animal models for skin delivery 
Several animals have been used for skin research including: 
mouse pigs, rabbits, guinea pigs, rats, and NHP’s.  The most common 
is the mouse, though this model has several disadvantages when 
compared to human skin.  Mice have very thin skin, lots of hair 
follicles, and have a panniculus carnosus (layer of muscle beneath the 
dermis, not present in human skin).  A better model for comparison to 
human skin is the guinea pig.  Guinea pigs have langerhans cells in the 
epidermis, a dermal elastic fiber network, and contain fibroblasts, 
monocytes, and macrophages.  A second model considered good for 
comparison to human skin is the pig   Pigs have a thick epidermis, a 
spare hair coat, well differentiated papillary body in the dermis and 
elastic fiber network [61, 62].  An equally appropriate small rodent 
model is the Hairless guinea pig. This model in addition to having the 
same benefits as the traditional haired guinea pig also has a thick 
epidermis with distinct strata, serrated/non-serrated basal 
keratinocytes, a papillary dermal layer, and superficial 
microvasculature [63] 
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Electrode development for the skin 
Several types of electrodes have been developed for use in the 
skin.  These electrodes include: NPE’s like plate, tweezer and caliper 
electrodes as well as PE and microneedle electrodes.  Both types 
consist of single or multiple electrodes in various conformations 
intended to optimize plasmid delivery and expression [60].   
Penetrating Electrodes 
Penetrating skin electrodes consist of needle electrodes in 
various configurations.  The PE’s utilized in the skin were reviewed 
thoroughly by Gothelf et al [60] and included in Table 4 below.  These 
electrodes range in electric fields (50-1800 V/cm), duration (50us to 
650ms) and pulse number (1-18) depending on electrode design.  The 
success of this type of electrode was recently published demonstrating 
the effective enhancement of transgene production in porcine skin 
[64].  Several PE’s have been evaluated for the development of 
immunity against various infectious agents [60].  The most recent of 
these have demonstrated enhanced humoral and cell mediated 
immunity in comparison to DNA alone. 
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 Non-Penetrating electrodes 
 NPE’s have also been utilized for skin EP and provide the 
advantage of not being inserted into the skin.  Early NPE’s consisted 
primarily of two plated electrodes like caliper and tweezer electrodes 
that were squeezed to contact the skin surface.  This generated 
variability in the distance between plates when applying pulses.  While 
these electrodes were somewhat effective, experimentation revealed 
that DNA uptake and expression could be increased by applying 
electrical pulses in multiple directions.  Therefore the Heller lab 
designed the 4PE.  This electrode consisted of four plates with a non-
conductive stopper that held the distance between the plates constant 
reducing variability when pulsing.  The Heller lab found that expression 
using this electrode was significantly increased over IO and was 
consistent with other plate electrodes.  However, due to the 6mm 
distance between the plates in this electrode the absolute voltage 
necessary for optimal expression generated pain. 
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Table 3.   Published Non-Penetrating Electrodes.   
  
Plate Electrode- Adjustable or Fixed Distance   
Reference Voltage Duration Number 
Titomirov 1991 400-600V/cm 100- 300µs 2 
Zhang 1996 120V 10-20ms 3 
Drabick 2001 1750V 100µs 6 
Heller 2001 100V/cm 20ms 8 
  1500V/cm 100µs 8 
Lucas 2001 100V/cm 20ms 8 
  1500V/cm 100µs 8 
  
750 + 14 + 
EEPV/cm 
50µs + 20ms + 
20ms 
2 + 4 + 
1 
Maruyama 2001 12- 24V 50ms 8 
Chesnoy 2002 200-400V/cm 20ms 10 
Zhang 2002 50-100V 15-30ms 3 to 30 
  75V 20ms 1 to 12 
  100V/cm 2ms 60 
Lee 2004 200-400V/cm 20ms 6 
Medi 2005 50V 30ms 10 
  100V/cm 10-30ms 5 
  100-300V 10ms 5 
Pavselj 2005 200V/cm 400ms 1 
  250V/cm 20ms 6 
  1000V/cm 100µs 1 
  1750V/cm 100µs 6 
  
1000 + 140-
200V/cm 100µs + 400ms 1 + 1 
  700 + 200V/cm 100µs + 400ms 1 + 1 
Thanaketpaisarn 
2005 50-1000V/cm 5ms 12 
Gao 2007 800V/cm 20ms 6 
Heller 2007 100V/cm 2ms 8 
Vandermeulen 2007 700 + 200V/cm 100µs + 400ms 1 + 1 
Andre 2008 
1000 + 80- 
200V/cm 100µs + 400ms 1 + 1 
Vandermeulen 2009 700 + 200V/cm 100µs + 400ms 1 + 1 
Gothelf 2011 1000 + 100V/cm 100µs + 400ms 1 + 1 
Gothelf 2011 
1000 + 80-
160V/cm 100µs + 400ms 1 + 1 
*Table continues on next page.  Table reconstructed from 
Gothelf et al 2011 [60] 
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Wires on skin- Custom built clips- Flat patches- MEA- 4PE  
Dujardin 2001 335V 0.5ms 10 
 335V 5ms 10 
 1000V/cm 100µs 10 
Heller 2001 1500V/cm 100µs 8 
Zhang 2002 75V 20ms 6 
Babiuk 2003 60-80V 60ms 6 
Heller 2007 10-1500V/cm 0.1-2000ms 8 
Pedron-Mazoyer 2007 60-240V 20ms 8 
Heller 2008 100V/cm 150ms 8 
Mazeres 2009 60-240V 20ms 8 
Heller 2009 100- 300V/cm 150-300ms 4 
Table 3 cont. 
*Table reconstructed from Gothelf et al 2011 [60] 
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Table 4.   Published Penetrating Electrodes.   
Needle Electrodes- Needle Arrays     
Reference Voltage Duration Number 
Glasspool- Malone 
2000 1750V/cm 100µs 6 
Drabick 2001 1500V/cm 100µs 2 to 6 
  1750V/cm 100µs 2 to 6 
  2000V/cm 100µs 2 to 6 
Byrnes 2004 200-400V/cm 20ms 6 
  400-1800V/cm 20ms 6 
  1750V/cm 100µs 6 to 18 
Marti 2004 1800V/cm 100µs 6 
Lin 2006 1800V/cm 100µs 6 
Roos 2006 200V/cm 100µs 6 
  275V/cm 10ms 8 
  1125V/cm 50µs 2 
  1750V/cm 100µs 6 
  1125 + 275V/cm 50µs + 10ms 2 + 8 
Zhao 2006 200V/cm 650ms * 
Kang 2008 50-250V/cm 100ms 6 
Liu 2008 400V/cm 20ms 10 
Brave 2009 1125 + 275V/cm 50µs + 10ms 2 + 8 
Ferraro 2009 200V/cm 20ms 8 
Lladser 2009 1125 + 275V/cm 50µs + 10ms 2 + 8 
Roos 2009 1125 + 275V/cm 50µs + 10ms 2 + 8 
Gothelf 2011 
1000 + 8-
140V/cm 
100µs + 
400ms 1 + 1 
Needles Parallel to Skin Surface- Syringes- Plate and Fork 
Electrodes 
Maruyama 2001 12-50V 50ms 8 
Lee 2004 50-200V/cm 20ms 6 
*Table reconstructed from Gothelf et al 2011 [60] 
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  Multielectrode Array 
 The MEA was designed to improve upon the 4PE.  It is a 16 
electrode array with 2mm spacing between electrodes. The reduced 
distance between electrodes decreases the absolute voltage applied 
while maintaining the electric Field (V/cm).  For example, using the 
4PE an electric field of 300V/cm would equate to applying an absolute 
voltage of 180 Volts (V=EF * (6/10)), whereas that same electric field 
would equate to an absolute voltage of 60 Volts (V=EF * (2/10)) using 
the MEA.   
Our initial publications using the MEA to enhance gene 
expression demonstrated that the MEA was capable of inducing similar 
gene expression in guinea pigs and rats as conventional electrodes and 
that the level of expression was related to the duration and field 
strength applied[55, 65].  GFP results, demonstrate that expression 
was contained within the epidermis [1].  Muscle twitching from 
treatment was greatly reduced in both guinea pigs and rats [1, 55].  
Finally, tissue damage from treatment was minimal and completely 
recoverable in 1 to 2 weeks [1]. 
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Figure 2.  Non-invasive 
Multielectrode array.  The MEA 
is designed with 16 electrodes 
spaced 2mm apart in a 4X4 
square.  The electrodes are round 
and gold plated with flat heads. 
[1] 
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Infectious Disease Models 
Bacillus anthracis 
Bacillus anthracis is a gram positive spore forming rod-shaped 
bacterium.  In vivo the rods appear in short chains surrounded by a 
polypeptide capsule [66].  The Centers for Disease Control and 
Prevention classify B. anthracis as a category A agent because it “can 
be easily disseminated or transmitted from person to person, results in 
high mortality rates and have the potential for major public health 
impact, might cause public panic and social disruption, and requires 
special action for public health preparedness.”   It is found readily in 
soil and was historically a disease of livestock. Full virulence requires 
an anti-phagocytic capsule, and three toxin proteins.  
Sporulation occurs from the presence of nutrient limited 
environment.  In the case of B. anthracis, spores have been 
demonstrated to survive for decades and are demonstrated to aid in 
dissemination of bacterium.  The spore structure is made up of five 
parts:  the core, cortex, coat, innerspace, and the exosporium. The 
exosporium contains several proteins that may play a role in 
vaccination.  One exosporium B. anthracis protein that has been 
extensively studied is Bacillus collagen like protein A.  This protein has 
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been shown to function in mediating the specificity of B. anthracis 
spores to be taken up by macrophages [67, 68] 
There are two toxins produced by B. anthracis that are of 
importance for clinical disease progression.  They are edema toxin and 
lethal toxin.  These binary toxins are comprised of protective antigen 
(PA) and either edema factor (EF) or lethal factor (LF) all produced 
after spore germination.  The protective antigen protein is an 83Kda 
protein in its inactive state.  It is cleaved by furin-like proteases to its 
63Kda active [69].  Several active PA’s come together to form either 
the heptameric or the highly stable octameric (common under normal 
physiologic pH and temperatures) prepore [70-72].  Multiple copies of 
the LF and EF bind to the PA prepore and are endocytosed and 
transferred into an acidic compartment.  The PA prepore channel 
undergoes a conformation change and insert into the membrane 
forming a cation selective channel.  The PA channel unfolds and using 
gradient that develops across the endosomal membrane translocates 
LF and EF into the cytosol [73-75]   
Edema toxin is a calmodulin-dependent adenylate cyclase that 
alters water homeostasis causing edema and impairs neutrophil 
function, rendering the host further susceptible to infection [76]. 
Lethal toxin leads to the release of reactive oxygen intermediates as 
well as the production of proinflammatory cytokines tumor necrosis 
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factor and interleukin-1b responsible for rapid circulatory collapse 
leading to disruption of MAPKK pathways and cell death [77, 78]. 
Clinical disease 
 B. anthracis causes anthrax disease, originally known as wool-
sorters, because it was those individuals that primarily acquired the 
disease from spore infested wool. Anthrax has three clinical 
manifestations. The first, cutaneous anthrax, acquired through a break 
in the skin, is usually self-limiting.  This form of anthrax is estimated 
to account for greater than 90% of human anthrax cases in the world 
[79].  The second and slightly more severe is gastrointestinal, which is 
acquired through ingestion of infected meat.  Mortality rates with 
antibiotic treatment are about 40% [66].  The final and most life 
threatening form, known as pulmonary anthrax, is caused by inhaling 
B. anthracis spores into the lungs.  Upon inhalation spores are taken 
into the alveolar spaces and engulfed by alveolar macrophages.  They 
are transferred to the lymph nodes, where germination occurs.  Upon 
germination of spores, toxins are produced that lead to flu-like 
symptoms and progress to toxemia and death from shock and multi 
organ failure [78]. 
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Anthrax Vaccine Adsorbed and novel vaccines 
The current available vaccine is a recombinant protein vaccine 
delivered intramuscularly in a 5 regimen dose over the course of 18 
months.  Following this series, annual boosters are recommended 
[80].  The protein is isolated from a toxigenic non-encapsulated form 
of the bacterium V770-NPR1 [80-85].  Side effects have been noted in 
approximately one-third of vaccinated individuals including: injection 
site swelling, redness, and tenderness [86].  The primary component 
of this vaccine is PA [83].  Research demonstrates that some 
antibodies formed against PA can prevent toxin formation which is a 
critical component of vaccine development [87, 88].  For this reason 
most research conducted for the formulation of novel B. anthracis 
vaccines has utilized PA as a target.   
These PA vaccines have been shown to have varying success 
upon challenge [3, 4, 80-82, 84, 85, 89-92].  Augmented rPA vaccines 
have been combined with CpG ODN, bacterial DNA fragments, E. coli 
LPS, complement receptors for targeting APC’s, and complement C3d.  
Recombinant PA has been combined with various other B. anthracis 
components including inactivated spores, LF and or EF, capsule 
gamma DPGA, and unencapsulated spores.  Some protection was 
shown from PA DNA vaccination but not against fully virulent strains 
unless combined with other agents [89].  Recently, a study evaluating 
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an IM EP mediated PA DNA vaccine was published.  Their results 
demonstrated the value of this technology, by achieving survival in 4 
of 5 NHP’s against an aerosol challenge of B. anthracis [93].  
 
Hepatitis B Virus 
 HBV is a member of the Hepadnaviradea family whose 
genome is made up of circular DNA.  As its name suggests, this family 
of viruses causes infections of the liver.  Liver disease from HBV can 
present in a variety of ways from fulminant hepatitis, cirrhosis, or 
hepatocellular carcinoma.  Approximately 15-40% of chronic HBV 
sufferers will develop significant liver disease.   The main components 
of this virus are: surface and core antigens, DNA polymerase, and an x 
antigen of unknown function [94].  There are 8 known genotypes of 
HBV denoted A through H [95].   
The current vaccine for HBV is a recombinant protein vaccine 
derived in yeast.  The protein used in this vaccine is recombinant 
HBsAg.  This vaccine is a 3 course vaccine given to infants within the 
first two months after birth.  Current data shows that vaccination with 
this vaccine lasts long term and that additional boosters are not 
necessary for properly vaccinated immunocompetent individuals [96]. 
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For this reason, it is an appropriate candidate for comparison of our 
vaccine model.  Established protective levels of anti-HBs titers are 
greater than 10mIU/ml. 
 
Significance 
The development of vaccines has been hampered by the 
emergence of infectious agents and lack of new techniques.  Novel 
methods like DNA vaccination provide a useful alternative to traditional 
methods by providing ease of production, stability in transport, small 
amounts necessary.  Unfortunately, DNA vaccines delivered directly 
have been ineffective and require the use of alternate delivery 
techniques.  EP has been shown to effectively increase gene 
expression as well as humoral and CMI with DNA vaccination.  Our 
model for DNA vaccination involves the use of a novel NPE, the MEA, 
for the induction of humoral immunity.  This electrode lays flat on the 
skin’s surface and is applied after intradermal injection.  This method 
is far less invasive and is more “friendly” for the patient.   
Additionally, when evaluating novel methods of DNA vaccination 
it is important to evaluate clinically relevant infectious models to 
determine the viability of your method.  B. anthracis is the causative 
agent of anthrax and a potential threat for use as a bioweapon. 
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 Finally, quite often when evaluating new methods appropriate 
animal models are sometimes not used and fail to appropriately 
determine what the possible effect will be in humans.  We have utilized 
the guinea pig model to more accurately reflect the effect of the MEA 
on human skin.  This study is significant because it not only 
demonstrates a novel method for DNA vaccination but also evaluates 
the effectiveness of this method for immunogenicity as well as 
translation to the clinic. 
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Goals and Objectives 
 
Purpose 
 The purpose of this study was to assess the functionality of the 
MEA for use in DNA vaccination.  In particular for the development of 
humoral immunity against the clinically relevant BA infectious model in 
mice as well as translational relevance by vaccination in a human like 
skin model.  This study evaluates the effects of both plasmid and EP 
has on generation of humoral immunity as well as the effect of EP with 
the MEA on the skin. 
 
Hypothesis 
 Electrically mediated DNA vaccination with the MEA will enhance 
immune stimulation against BAs in a mouse model and HBV in a 
human-like skin model, guinea pigs. 
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Specific Aims 
Aim 1: Determine the effect of electrically mediated delivery with the 
Multi-Electrode Array on plasmid expression in mouse skin 
a. Compare gene expression from electroporation with the Multi-
Electrode Array at various field strengths to the optimized 
skin (4PE) and muscle (4 needle) electrodes. 
b. Evaluate the tissue damage and inflammation caused by MEA 
mediated electroporation by histology and visual assessment. 
c. Evaluate differences in the gene expression profile from MEA 
mediated EP at high and low electric fields. 
 
Aim 2:  Determine the effect of electrically mediated delivery with the 
MEA on immune stimulation against B. anthracis  
Sub aim a:  Purification of PA plasmid and confirmation of 
expression in vitro. 
1.  Plasmid purification and digestion 
2. PA expression in vitro 
3. MEA mediated DNA vaccination with PA plasmids 
induces anti-PA antibodies in vivo 
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Sub aim b:  Determine the appropriate delivery conditions for 
induction of humoral immunity against B. anthracis. 
1. Evaluate the effect of plasmid dose on MEA mediated 
humoral immune stimulation 
2. Evaluate the effect of number of treatments on MEA 
mediated humoral immune stimulation 
3. Evaluate the electric field effect of MEA mediated humoral 
immune stimulation 
Sub aim c:  Determine the in vitro protective potential of the 
optimized delivery conditions 
Aim 3:  Evaluate the potential for translation of electrically mediated 
delivery with the MEA in a human-like skin model. 
a. Evaluate the effect of MEA mediated EP on human-like skin by 
histological analysis and visual assessment 
b. Evaluate MEA mediated DNA vaccine expression in a human-
like skin model. 
c. Determine the humoral stimulation from MEA mediated DNA 
vaccination against HBV 
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Materials and Methods 
 
General Methods 
Plasmid purification.  Plasmid DNA was produced by transformation 
into E. Coli XL-10 gold cells.   Transformed cells were plated on 
antibiotic resistant LB agar (Ampicillin 100ug/ml or Kanamycin 
50ug/ml) and incubated overnight at 37°C.  Colonies were picked and 
cultured in 2.5 Liters of antibiotic containing media.  Plasmid was 
isolated using Qiagen plasmid Giga-prep kit per manufacturer’s 
protocol.  Briefly, cultures were spun down at 3000 rpm for 30 minutes 
at 4°C.  The bacterial pellet was resuspended in 125 ml of Buffer P1.  
125mls of Buffer P2 was added and inverted 5 times to mix and 
incubated for 5 minutes at room temperature.  125mls of Buffer P3 
was added and mixture was added to the Qiafilter and allowed to 
incubate for 10 minutes.  Mixture was vacuum filtered and 30mls of 
Buffer ER was added and incubated on ice for 30 minutes.  Qiatip 1000 
was equilibrated with 75mls Buffer QBT.  Mixture was added to Qiatip 
to bind DNA.  Tip was washed with 600mls Buffer QC.  DNA was eluted 
with 100mls of Buffer QT.  DNA precipitation was performed with 
70mls of isopropanol and spun at 15000 x g for 30 minutes at 4°C.  
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DNA pellet was washed with 70% Ethanol and respun for 10 minutes.  
Pellet was air dried and resuspended at 2mg/ml in physiological saline. 
 
Cell Lines and Complete Growth Medium: B16F10 cells were 
purchased from ATCC and grown in McCoy's 5A media supplemented 
with 10% FBS and Gentamycin.  J774A.1 Macrophages were also 
purchased from ATCC and were grown in DMEM supplemented with 
5% FBS, 10mM HEPES Buffer, and Pen-Strep. 
 
DNA Digestion:  PA plasmids were digested with restriction enzymes 
NotI or KpnI and incubated at 37°C for 1.5 hours.  6X loading dye was 
added to stop the digestion and run on a 1% agarose gel with HindIII 
lambda marker.  The gel was run at 100V for 1 hour.  The gel was 
incubated for 15 minutes in Ethidium Bromide and UV light used to 
visualize the resulting bands. 
 
Mouse model methods 
Ethics Statement:  Animal procedures were conducted at either USF 
vivarium, which is fully accredited by the Association for the 
Assessment and Accreditation of Laboratory Animal Care (AAALAC) 
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and the Public Health Service (PHS), or Old Dominion University 
Center for Bioelectrics' vivarium, which is currently undergoing 
AAALAC accreditation.  Research was conducted under protocols 
approved by the Institutional Animal Care and Use Committee (IACUC) 
at both institutions (protocol # 10-006).  All animals were housed, 
handled and utilized following guidelines of the United States National 
Institutes of Health. 
 
Animals and injections:  6-8 week old female Balb/c mice were 
intradermally injected at two sites on the left flank with 50µl of 
plasmid for experimental animals.  Experimental mice were boosted 
either once or twice 14 days after the previous treatment (Day 14, 
Day 28).  All experiments included control animals of 10µg muscle 
injected recombinant protein as well as injection only.  Recombinant 
protein injections were administered at Day 0, 14, and 28.  Mice were 
bled by tail vein at various time-points.    All animals were 
anesthetized with 2-3% isoflurane + O2 for treatments. 
 
Plasmids: The plasmids used for these experiments were pSecTagPA 
and pCMVER/PA at various concentrations for B. anthracis studies.  
The PA plasmids were generously donated by the Hahn lab (University 
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of Hoenheim, Germany).  Reporter assays were done using pGwizLuc 
and pGwizGFP (Aldevron) also at 2mg/ml. 
Electroporation:  The MEA was used at applied electric fields ranging 
from 25 to 225V/cm but always maintained constant pulse duration 
and delay of 150ms.  A sequence of 9 4X4 squares was applied 4 
times for a total of 72 pulses.  Electrodes were circular, gold plated 
and flat at the end with a 0.2mm diameter.   
 
In vivo Bioluminescent Imaging:  The Caliper life sciences IVIS 
Spectrum was used for live animal bioluminescent imaging.  Animals 
were injected i.p with 15mg/ml luciferin.  20 minutes post luciferin 
injection the animals were imaged and relative light units measured.  
All luciferase data is represented as average total flux 
(photons/sec/sec) per injection site.   
 
Tissue Collection and sectioning:  Mouse skin was collected at 
various time points from 24-72 hours and up to 7 days after 
treatment.  Mice were humanely euthanized using CO2 asphyxiation. 
Tissue was marked at time of treatment to notate the region to be 
removed.  Skin samples were immediately placed on dry ice or in 
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formalin for sectioning.  Frozen skin sections were sliced using the 
Thermo Fisher cryostat 550 at -17C in OCT medium 
 
Immunohistochemistry:  Sections were placed on slides and fixed 
for twenty minutes in 75% Acetone and 25% Methanol and placed at -
80°C until imaging. Slides were blocked for 1 hour in PBS with10% 
goat serum at room temperature in the dark.  FITC conjugated goat 
anti-GFP antibody diluted 1:500 in blocking buffer was added 
overnight at 4°C.  Slides were washed with PBS and Dapi added to 
visualize nuclei.  Slides were imaged immediately to prevent loss of 
fluorescence. 
 
Histology:  Skin samples were taken from both mice for histological 
analysis.  Mouse skin was collected 48 hours after treatment and fixed 
in formalin.  H & E staining was performed to assess inflammation and 
damage. 
 
Sandwich ELISA for PA detection: Anti-PA coating antibody (Abcam 
18725) was diluted 5µg/ml in 50mM Sodium Carbonate.  100ul of 
coating buffer was added to each well and incubated overnight at 4°C.  
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The next day the plate was blocked with PBST + BSA for 2 hours at 
37°C.  Supernatants were added directly to each well with 100µl, 
lysates were lysed with NP40 buffer (100ml of 100mM Trizma pH 8.0, 
50ml Glycerol, 5ml Triton X100, 4g NaCl, 10ml of 100mM EDTA pH 
7.4, diH2O) for 30 minutes on ice.  PA antigen (List Biologicals 171B) 
was used as a control to quantitate amount of PA present.   PA was 
diluted to 10000ng/ml and 100µl added to each well for standards.  
Four fold dilutions were made to generate a standard curve.  Samples 
were incubated for 2 hours at 37°C.  Wells were washed with PBST 5 
times.  Secondary was (Abcam 18723) added for 1 hour at room 
temperature.  Secondary was diluted to 1ug/ml and 50ul added to 
each well.  AP conjugated antibody was added for 1hr in dark at room 
temperature.  To colorize, pNPP (Sigma) was added and the plate was 
read at 405nm. 
 
Indirect ELISA for the determination of antibodies:  Briefly, 
antigen was coated at 0.1 to 1µg/well and incubated overnight at 4°C.  
Plates were blocked with either BSA-PBST (anti-HBs) or 5% skim milk 
buffer (anti-PA) for 2 hours at 37°C.  Samples were diluted in blocking 
buffer and incubated for 1 hour at 37°C.  HRP conjugated secondary 
antibodies (Santa Cruz) were diluted in blocking buffer to working 
concentration and added for 30 to 60 minutes in the dark.  R&D 
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substrate was added for 10 minutes and stopped with 2N H2SO4.  
Plates were read at 450nm and results represented as mean titers. 
 
Toxin neutralization assay: 50,000 cells/well of J774A.1 murine 
macrophages were plated in 96 well cell culture plates.  The next day 
serum was diluted starting at 1:50 in media and incubated for one 
hour with 100ng/ml protective antigen.  Lethal Factor was added to 
the Serum/Protective antigen mix at a final concentration of 80ng/ml.  
Media was removed from the cells and the serum/PA/LF mix was 
added to the macrophages for 4 hours at 37 and 5% CO2.  All plates 
contained a titration curve to confirm that the concentration of toxin 
used was sufficient to cause 95% cell death.  Following the 4 hour 
incubation, 25µl of MTT (5mg/ml) was added and incubated for an 
additional 2 hours.  Media was removed by vacuum suction and 100µl 
of DMSO was added to break up crystal formation.  Plate was read at 
560nm. 
 
Guinea Pig model methods 
Ethics Statement:  All animal procedures were conducted the 
University of South Florida, College of Medicine vivarium which is fully 
accredited by AAALAC and the PHS.  Research was conducted under a 
37 
 
protocol approved by the IACUC at the University of South Florida, 
College of Medicine (protocol # 2879).  All animals were housed, 
handled and utilizing following guidelines of the United States National 
Institutes of Health. 
 
Animals: Female Hartley guinea pigs between 200-250g were used in 
this study to evaluate skin EP conditions.  Guinea pigs were housed at 
the University of South Florida, College of Medicine vivarium and were 
rested for one week prior to experimentation.  Guinea pigs were 
anesthetized with 2.5-3.0% isoflurane before and during all 
procedures.  No previous exposure to HBV was known.  
 
Plasmid:  The plasmid used in this study was gWiz™ HBsAg 
(Aldevron, Fargo, ND).  This plasmid encodes for the surface antigen 
of Hepatitis B and is driven by the CMV promoter.   
 
Immunization: All guinea pigs were intradermally injected with 
100µg (2mg/ml) of gWiz™ HBsAg at two sites on the left flank.  MEA 
EP was performed at 300V/cm and 150ms and 72 pulses.  The two 
groups used in this study were control group injection of plasmid only 
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(IO) and injection of plasmid plus EP (I +EP).  All groups were boosted 
with the same condition at Day 14. 
 
Serum collection:  Guinea pigs were anesthetized with 2.5-3.0% 
isoflurane.  Blood was collected from the jugular vein at various time 
points from Day 0 through Day 168. Blood was collected and serum 
isolated in serum separator tubes.  Serum was diluted two-fold 
starting at 1:10. 
 
Tissue collection:  Guinea pigs were treated as described with 
gWiz™ HBsAg with and without EP.  Those guinea pigs whose tissue 
was collected for plasmid expression were sacrificed 48 hours after one 
treatment and skin samples were harvested by excising the treatment 
site and followed by freeing.  Those guinea pigs whose tissue was 
collected to assess damage and cell infiltrate were treated and 
harvested 96 hours after one treatment and the tissue was snap 
frozen. 
 
Indirect ELISA for the detection of Hepatitis B surface antigen 
antibodies: An ELISA was used to assess the production of antibodies 
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from treatment and performed per manufacturer’s protocol (Aldevron).  
Briefly, a 96-well plate (Nunc) was coated with 10µg/ml of HBsAg 
(Aldevron) and allowed to coat overnight at 4°C.  The plate was 
blocked with 3% BSA in PBST for 2 hours at 37°C.  Serum samples 
were two-fold diluted in blocking buffer and added to the plate for 2 
hours at 37°C.  Goat anti-Guinea pig-AP antibody was added at a 
1:10000 dilution in blocking buffer.  AP substrate, pNPP, (Sigma) was 
added to colorize and the plate was read at 405nm. 
 
Immunohistochemistry: An anti-HBsAg was used to detect plasmid 
expression.  Skin samples taken 48 hours after treatment were frozen, 
sectioned, and placed on slides.  Slides were rehydrated and then 
blocked with 3% BSA in PBST and incubated in a humidifying chamber 
for 1 hr.  A HRP conjugated anti-HBsAg (AbD Serotec) was made in 
blocking buffer at a 1:200 dilution.  All samples were counterstained 
with H & E.   
 
Histology:  Samples collected at 96 hours frozen, sectioned, and 
placed on slides were stained with H & E to determine the extent of 
cellular infiltrate/inflammation.   
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Statistical analysis:  All Guinea pigs were bled at Day 0 to determine 
background optical density (OD).  OD’s were averaged and 2 standard 
deviations added to determine positive (0.1 OD).  Experimental serum 
samples were diluted two-fold starting at 1:10.  End point titers were 
calculated and plotted as Geometric Means.  Significance was 
determined by student t-test using the bonferroni correction for 
multiple comparisons. 
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Results 
 
Aim 1: Determine the effect of electrically mediated delivery 
with the MEA on plasmid expression in mouse skin. 
 Introduction:   
 EP has been demonstrated to be an effective delivery platform 
for DNA.  However, it is limited in its use due to the current electrode 
designs.  Currently those electrodes require either high voltages that 
would not be tolerable for human use or PE’s that involve insertion into 
the tissue.  We have designed a novel electrode that both eliminates 
penetration of the electrode as well as reduces the absolute voltage 
necessary for delivery.  Here we establish that this devices elicits 
similar gene expression levels as the current devices with minimal to 
no damage.   
 
 
 
42 
 
a. Comparison of gene expression from EP with the MEA at 
various field strengths to the optimized skin (4PE) and 
muscle (4 needle) electrodes. 
 In order to assess the ability of the MEA to enhance gene 
expression in a mouse model, Balb/c mice were injected with 50ul of 
GwizLuc (2mg/ml) intradermally on the left flank.  Sites were 
electroporated with various electric fields with the MEA or 100V/cm 
with the 4PE.  A control group of injection of plasmid only was included 
Figure 3.  Luciferase Gene expression from MEA EP.  
GwizLuc plasmid (2mg/ml) was injected into the left 
flank of Balb/c mice.  Treatment sites were either EP with 
the MEA or 4PE at specified electric fields.  Control group 
of IO was also included. 
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Figure 4.  Effect of MEA mediated EP on mouse skin 
histology.  Balb/c mice were injected with plasmid DNA and EP 
to assess changes in skin from treatment.  Samples were 
collected 48 hours after treatment.  A)  No treatment.  B) IO of 
plasmid DNA.  C) Injection and EP with the MEA at 175V/cm. 
A B C 
(IO).  Figure 3 shows that using the MEA, luciferase expression can be 
increased and that the increase is field dependent.  Higher electric 
fields result in increased luciferase expression.  However, all MEA 
conditions are greater than IO and demonstrate similar expression 
patterns as the control 4PE animals over time.  Visual tissue damage 
was seen in animals treated with the MEA at 200V/cm.  Though this 
condition represented the highest level of gene expression with the 
MEA conditions above 175V/cm will not be used to prevent potential 
tissue damage.  
b. Evaluate tissue damage and inflammation caused by MEA 
mediated EP by histology and visual assessment. 
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 Histology was performed to evaluate the skin tissue for damage 
at 175V/cm.  IO samples show no gross visual difference in swelling or 
skin damage from EP treated animals.  Histologically, however, (figure 
4 a & b) EP samples showed a large influx of cellular infiltrate 
c. Evaluate the differences in DNA uptake from MEA mediated 
EP at  high and low electric fields 
Expression of plasmid DNA at high and low electric fields was 
evaluated using GFP.  The use of GFP instead of Luciferase allows us to 
visualize the location and number of cells expressing the protein as 
opposed to total expression.  Here we were able to evaluate whether 
these electric fields have different DNA distribution after EP and 
subsequent differences in expression.  Figure 5, shows MEA EP at 
125V/cm and MEA EP 175V/cm for both 24 and 48 hours after EP.  
Enhanced expression from EP can be seen in both 125 and 175V/cm 
conditions at different time points.  EP with 125V/cm demonstrates the 
highest quality expression.  EP with 125V/cm has good distribution of 
expression along the epidermis and is more pronounced at 48 hours.   
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Figure 5.  GFP expression from MEA mediated EP at 
various conditions.  Mice were injected with pGwizGFP 
plasmid (C-E) and EP at either 125V/cm (C and D) or 
175V/cm (E and F).  Skin was collected and snap frozen at 
24 ( A, C, and E) and 48 (B, D, and F) hours after 
treatment.   
A B 
C D 
E F 
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Aim 2: Determine the effect of electrically mediated delivery 
with the MEA on immune stimulation against B. anthracis. 
Introduction 
B. anthracis is of clinical relevance as a bioterrorism weapon.  
The current available vaccine has several side effects that range from 
mild to severe and requires several initial vaccinations followed by 
annual boosters.  The vaccine is a recombinant protein vaccine and 
therefore a good candidate for development of a new vaccine model.  
Our group, and others, proposed the use of DNA vaccines to generate 
lasting immunity against this threat. In 2004, the Hahn group 
constructed two plasmids expressing full length PA.  These plasmids 
were designed to secrete PA (pSecTagPA; Fig 6A) and bind to the 
membrane (pCMVER/PA; Fig 6B).   
 Their results demonstrated that these plasmids when delivered 
by the gene gun could generate humoral immunity including antibodies 
against neutralizing epitopes of PA.  Here we utilize these established 
plasmids to determine whether EP with the MEA can generate humoral 
and neutralizing immunity against B. anthracis and those conditions of 
the MEA that are best suited for developing immunity. 
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A 
B 
Figure 6  Protective antigen plasmid constructs.  Construction of 
the PA plasmids used in this study was done by the Hahn lab and 
published in 2004 in Vaccine. Both plasmid backbones were 
commercially made by Invitrogen and  are designed to express full 
length PA under control of the CMV promoter A) pCMVER/PA contains 
a sequence for targeting expression to the endoplasmic reticulum.   
B) pSecTagPA contains a secretion sequence. 
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Sub aim a:  Confirmation of expression of PA plasmids in 
 vitro and in vivo 
1.  PA plasmid preparation and isolation 
 PA plasmids were prepared as described in Methods and digested 
with NotI (pCMVER/PA) and KpnI (pSecTagPA).  The resulting digests, 
shown in figure 7, show undigested and digested plasmid.  Lane 1 is 
the HindIII lambda marker.  Lanes 2 and 3 are undigested and 
digested pCMVER/PA respectively.  Lanes 4 and 5 are undigested and 
digested pSecTagPA respectively.  The bands for pCMVER/PA are seen 
at 7230bp corresponding to a correctly linearized plasmid.  The band 
for pSecTagPA corresponds to 7299bp, again a correctly linearized 
plasmid.  Both plasmids were purified cleanly and linearize 
appropriately and can be used for further work.  
 
  
49 
 
Figure 7.Isolation and Purification of PA 
plasmids.PA plasmids were isolated and prepped 
using the Giga prep kit from Qiagen.  Once 
isolated plasmids were confirmed by DNA 
digestion.  Lane 1 is the HindIII lambda marker.  
Lane 3 is NotI digested pCMVER/PA.  Lane 2 is 
undigested.  Lane 5 is KpnI digested pSecTagPA.  
Lane 4 is undigested. 
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2. Expression of PA plasmids in vitro 
 PA plasmids were transfected into B16 F10 mouse melanoma 
cells in vitro to confirm that PA was being expressed by the plasmids.  
B16 F10 cells were selected because our lab had generated standard 
protocols for transfecting this type of cells.  Since the goal of this 
experiment was to confirm that the plasmids expressed PA, the cell 
type used was not critical as long as they were susceptible to 
transfection and were not killed by expression of the protein.  Cells 
were transfected and supernatants and lysates collected after 48 
hours.  The results in figure 8 demonstrate that the secreting plasmid 
has more PA expressed in the supernatant as compared to the 
endoplasmic reticulum targeted plasmid.  While there is more PA 
expressed from the ER plasmid, most of the protein is found within the 
lysate.  The relatively even expression of PA between the lysate and 
supernatant in the secreted plasmids reflects a two fold increase in 
secretion as compared to the ER plasmid.  Total expression is about 
the same between the two plasmids with the secreted plasmid 
producing about 10000pg/ml and the ER plasmid producing about 
11500pg/ml. 
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Figure 8.  In vitro expression of PA plasmids in B16 
F10 cells.  Both PA plasmids were transfected into B16 
F10 cells and supernatant and lysates were collected 
after 72 hours.  Sandwich ELISA was performed to 
quantitate expression of PA.  rPA was used as a standard 
for quantitation. 
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3. PA plasmids in vivo. 
 PA plasmids were injected into the left flank of Balb/c mice and 
electroporated with the MEA at 225V/cm.  Each plasmid was injected 
individually and at a 1:1 combination to determine the amount of 
antibody produced by each and together.  Shown in figure 9, the 
highest level of antibody production was seen with vaccination with the 
Figure 9.  In vivo Injection of PA plasmids for the 
development of anti-PA antibodies.  PA plasmids were 
injected into the left flank as described in Methods and EP at 
225V/cm with either PA plasmids individually or at a 1:1 
combination.  #= value is zero 
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pCMVER/PA plasmid; however, antibodies were not seen until 6 weeks 
after initial vaccination.  Vaccination with pSecTagPA produced 
antibodies as early as 3 weeks after treatment.  Whereas vaccination 
with the 1:1 combination resulted in both an early response and 
demonstrated similar (even slightly increased) antibody levels as 
compared to pCMVER/PA.  Based on these results, the 1:1 combination 
was selected for use in all future experiments.   
 EP with the MEA was compared to other EP devices to determine 
the effectiveness of antibody production with this electrode. The 4PE 
was used as an alternative skin electrode for comparison of skin EP 
and the 4 needle was used to facilitate comparison to muscle EP.  DNA 
was injected into the left flank for skin EP as described in methods.  
Muscle groups were injected into the gastrocnemius and the electrode 
inserted into the muscle around the injection site and EP administered.  
Figure 10, shows that at early timepoints IO animals have higher 
expression than muscle injected groups demonstrating the benefit of 
using skin as the delivery location.  Also at week 3 EP, regardless of 
electrode type, increases antibody production as compared to IO but 
are not different from each other.   MEA EP samples increase steadily 
over time whereas muscle EP animals peak by week 9 and begin to 
drop off by week 12.  Additionally, when comparing MEA skin delivered 
groups to 4PE skin delivered groups there is a noticeable difference in 
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antibody production.  It is important to note, that even with lower 
levels of expression, Figure 3, the MEA can produce equal or slightly 
greater antibody production compared to the 4PE. 
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Figure 10.  Comparison of MEA mediated in vivo delivery 
with other EP devices for antibody production.  PA plasmids 
were combined 1:1 and injected into Balb/c mice.  MEA and 4PE 
delivered plasmids were injected i.d., whereas 4 needle delivered 
plasmid was injected into the gastrocnemius.  Serum was 
collected over time by tail vein bleed.  IO= Injection only; MIO= 
Muscle Injection only; ME+ 100V/cm= Muscle + Electroporation at 
100V/cm; 4PE 100V/cm= four plate electrode at 100V/cm; MEA 
175V/cm= Multielectrode array at 175V/cm.  #= value is zero. 
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Sub Aim b:  Optimization of delivery parameters for DNA  vaccination 
with the MEA against Bacillus anthracis 
 Introduction 
 Current experiments testing for vaccines against PA include 
recombinant protein, spore, and DNA constructs.  Most of these 
vaccines are derived from the PA protein of B. anthracis because 
antibodies against this protein have been shown to have neutralizing 
toxin properties.  However, several groups are also evaluating spore 
proteins either by DNA delivery, recombinant protein or inactivated 
whole spores.  These vaccines have been shown to have some efficacy 
but are not capable of generating responses against toxin components.  
The DNA based vaccines, have tested both toxin and spore 
components.  Two groups have tested the efficacy of muscle EP 
delivery of PA DNA.  Their results demonstrated that this method can 
be used to generate total and neutralizing antibodies.  As previously 
stated our goal is to use non-invasive EP, namely the MEA, to generate 
these responses.  However, the EP and DNA delivery conditions cannot 
be assumed to be the same as in muscle delivery.  Here we assess the 
appropriate delivery conditions for i.d. DNA vaccination against B. 
anthracis with the MEA.  The three parameters tested were:  plasmid 
dose, number of treatments, and electric field.   
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1. Identification of plasmid dose necessary for optimal 
DNA vaccination against B. anthracis.  
 Plasmid DNA was injected into the left flank of Balb/c mice in 
various amounts from 100-300ug.  EP with the MEA at 225V/cm was 
used for all plasmid doses.  IO was delivered at 200ug.  Antibody 
responses were measured by ELISA.  The results, Figure 11, show very 
little differences in antibody production.  There was no detectable 
response from IO animals at weeks 3 and 6.   All conditions are 
increased above IO at all time points.  However, at early timepoints 
200µg seems to be slightly increased over 100µg and 300µg.  By week 
9, 300µg had surpassed 200µg and maintained at week 12.  These 
results do not generate any significant benefit to increasing plasmid 
dose.  The largest differences affected by plasmid dose occurred at 
weeks 3-6.  Over this time 200µg of plasmid shows the largest 
differences between groups. For this reason, we have selected to 
continue further experimentation with that dose. 
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Figure 11.  Effect of Plasmid dosing on generation of 
antibodies from MEA mediated delivery.  Plasmid DNA 
ranging from 100 to 300ug was injected into the flank of Balb/c 
mice and EP with the MEA at 225V/cm.  Serum was collected 
over time by tail vein bleed.  #= value is zero. 
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2. Identification of the number of treatments necessary for 
optimal DNA vaccination against B. anthracis.  
 Animals were treated on either Day 0 and 14 or Day 0, 14, and 
28.  Antibodies were measured and plotted over time.  The results, 
Figure 12, again show very little differences in antibody production.  
All groups increase over time and are increased over IO.  However, by 
week 12 the group receiving the third treatment has begun to drop off, 
whereas the two treatment group is still increasing.  This data 
demonstrates that there is not an additional benefit gained from a 
third treatment.  All further experiments were conducted with a two 
treatment protocol at Days 0 and 14. 
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Figure 12.  Evaluation of number of treatments for 
generating MEA mediated antibody responses.  Plasmids 
were injected at Day 0 and 14 or Day 0, 14, and 28.  Each 
treatment was immediately followed by EP at 175V/cm.  Serum 
was collected over time by tail vein bleed.  #= value is zero. 
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3. Identification of the electric field necessary for optimal 
DNA vaccination against B. anthracis.  
 Mice were injected with PA plasmid DNA and followed 
immediately with EP at electric fields from 25 to 175V/cm.  Serum was 
collected and antibodies measured over time.  Results, Figure 13, 
show that electric field does significantly affect antibody production.  
Statistical significance was determined using ANOVA with the Tukey-
Kramer multiple comparisons test.  Electric fields below 125V/cm 
generate significantly less antibodies than 125 (weeks 9 and 12) and 
175V/cm (week 12).  Both 125 and 175V/cm are significantly 
increased over IO at weeks 9 and 12.  While not significantly different 
from each other, 125V/cm does induce slightly higher antibody 
responses than 175V/cm at all time points from 3-12 weeks. 
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Figure 13.  Evaluation of electric field from MEA mediated 
EP of PA plasmids for the generation of antibodies.  PA 
plasmids were injected into Balb/b/c mice and EP with the MEA at 
fields ranging from 25 to 175V/cm.  Serum was collected over 
time by tail vein bleed.  Statistical analysis was performed using 
ANOVA and the Tukey-Kramer multiple comparisons test. 
*=p<0.05 compared to IO; += p<0.05 compared to all lower EP 
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Sub aim c: Vaccine potential of the MEA against B. anthracis 
 The critical question is whether a protective immune response 
can be generated using this delivery method.  To assess this, a toxin 
neutralization assay was performed to determine the titer of 
neutralizing antibodies generated from our “optimized” delivery 
conditions.  MEA EP conditions for both 125 and 175V/cm were tested 
as both conditions generated significantly increased antibody 
responses as compared to lower conditions and IO (Figure13).  Table 5 
shows that 3 out of 5 mice could generate neutralizing antibodies  
using the MEA at 175V/cm and 2 out of 5 for 125V/cm.  IO and EP 
only groups did not have any neutralizing activity.   
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Table 5.  In vitro protection by Toxin Neutralization Assay.   
 
  
Condition Peak serum 
titer 
Serum 
Dilution 
# of mice with 
TNA’s 
pPA IO 3200 50 0 of 5 
Backbone + EP 
175V/cm 
0 50 0 of 5 
pPA + EP 175V/cm 12800 50 3 of 5 
pPA +EP 125V/cm 25600 50 2 of 5 
rPA 10µg i.m. 50000 50 5 of 5 
*Serum was diluted 1:50 and combined with PA to prevent toxin 
formation.  Peak serum titers are expressed as total average end 
point titers for each condition. 
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Aim 3: Evaluate the potential for translation of electrically 
mediated delivery with the MEA in a human-like skin model.1
 This is the beginning text of the section containing previously 
published information [97].  Utilizing the B. anthracis model allowed us 
to evaluate this approach for DNA vaccine delivery in a clinically 
relevant infectious disease model, it also needs to be understood that 
the approach and particularly the electrode array had not as yet been 
tested in humans.  Therefore, it was also important for us to evaluate 
the development of immunity and assess the condition of the skin from 
treatment with the MEA in a human like skin model.  The best small 
animal model for human skin is the guinea pig.  Their skin is 
approximately the same thickness (about 1mm) and contains similar 
properties for antigen presenting cells [63].  Hairless guinea pigs are 
the best model because while they still have hair follicles they do not 
possess the fur that normal guinea pigs do, however due to an 
infection in the hairless guinea pig population it was not feasible to use 
 
 Introduction 
                                                          
1 Portions of these results have been previously published (Donate, A et al 2011 [97]) and are utilized 
without need for publisher permissions due to the Creative Commons License.  Legal Code is included in 
Supplementary Materials.  Level of work contributed by Authors:  Amy Donate 70%, Yolmari Cruz 5%, 
Domenico Coppola M.D. 5%, and Richard Heller Ph.D. 20%. 
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Figure 14.  Gwiz™HBsAg plasmid. 
Map image from aldevron.com 
this model for vaccination testing.  Therefore, we used regular guinea 
pigs and their hair was shaved.   
 Our initial experiments with this guinea pig model were to 
evaluate expression at various EP conditions with the MEA and to 
compare those to our current 4PE skin electrode.  Our results 
published in Human Gene Therapy in 2010 demonstrated that the MEA 
was an efficient delivery electrode for gene expression in the guinea 
pig.  Luciferase expression equivalent to the 4PE could be achieved as 
low as 250 to 300V/cm and 150ms.  Additionally, we could increase 
gene expression by increasing the area of skin EP [65].  MEA EP with 
GFP plasmid showed that this expression was localized to the 
epidermal and dermal layers of the skin.  These results make the MEA 
a good candidate for vaccination in our human like skin model.   
a. Plasmid expression from EP. 
 The first step in 
evaluating the MEA for delivery 
of DNA vaccines in a human-
like model was to evaluate 
expression of gWiz™ HBsAg, 
Figure 14.  Guinea pigs 
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were treated as described in Methods with or without EP using the MEA 
at 300V/cm.  Guinea pigs were humanely euthanized 48 hours after 
delivery and the treated skin harvested and snap frozen.  Expression 
of HBsAg was determined by immunohistochemistry.   
 In Figure 15 A and B, expression of HBsAg is seen in IO and MEA 
EP samples. Increased staining compared to IO samples can be 
observed in the MEA EP samples.  Expression of HBsAg is seen within 
the epidermis of both groups, but is in much higher quantity in the 
MEA EP group.  Additionally, deeper expression into the dermis is also 
noted in the MEA EP condition.  It should also be noted that there is a 
slight separation of the epidermis in the MEA EP group.  This damage 
was evaluated in further experimentation and found to be minimal and 
completely recoverable over time, Figure 16. 
b. Immune cell infiltrate and tissue damage 
 Other than expression of plasmid DNA, another important factor 
for developing immunity is the recruitment of immune cell infiltrate. 
This is an important consideration especially for DNA vaccination 
because it can often be a limiting factor for this type of vaccine.  To 
test for this, skin sections were collected 96 hours after treatment, 
frozen, and stained with H & E.  Induction of immune cell infiltrate was 
observed (Fig 15 C-F 100X magnification).  Background levels, Fig 
15C, of infiltrate are demonstrated in no treatment control and 
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correspond to low levels of cellular infiltrate (purple).  IO samples 
show slight increases in infiltrate as compared to no treatment, Fig 
15D.  In contrast, MEA EP samples show a large increase in cellular 
infiltrate, Fig 15E.  The substantial influx of immune cells can be seen 
more clearly in figure 15F (200x magnification MEA EP).   
It is important to observe that edema was noted in all injected 
tissues.  This is most likely a result of the injection and not of the EP 
as it is seen in the IO samples as well.  Edema did not appear 
increased due to EP.  Additionally, in most samples, tissue damage 
and necrosis were not seen.  However, two EP delivered samples had 
minimal ulcerations at 96 hours after treatment, one of which also had 
about 1% necrosis.  There were no other samples showing damage or 
necrosis.  This is further evaluated by macroscopic evaluation of the 
skin.   Injection site redness is seen immediately after treatment, with 
a slight increase in redness in the MEA EP treated sites, Figure 16.  By 
48 hours after treatment most of the redness has cleared up and IO 
and MEA EP groups are indistinguishable from one another.  Complete 
visual recovery of the skin is seen by Day 7. 
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Figure 15.  Histological Assessment of Guinea 
pig Skin for Expression, Inflammation, and 
Damage from MEA Mediated EP.  Female guinea 
pigs were injected on the left flank with 
pGwizHBsAg.  Immunohistochemistry was 
performed to determine expression of HBsAg after 
48 hours A) IO and B) EP 300V/cm.  Skin samples 
were collected for H & E staining 96 hours after 
treatment with the MEA at 300V/cm.  C) No tx,     
D) IO, E) EP 300V/cm F) EP 300V/cm 200X 
magnification. 
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Figure 16.  Visual assessment of guinea 
pig skin for damage and recovery.  
Guinea pig skin was imaged immediately 
after treatment through Day 7 to determine 
damage and healing. 
70 
 
Figure 17.  Evaluation of the development of humoral 
immunity from MEA mediate EP in a human like skin 
model.  Guinea pigs were injected on the left flank and EP 
groups were immediately EP with the MEA at 300V/cm.  
Guinea pigs were bled by jugular vein over time and serum 
used for ELISA.  Both groups had an n-=18 from three 
independent experiments.  Statistical analysis was performed 
using a student t-test and bonferroni correction. 
c. Anti-Hepatitis B surface antigen antibodies 
 The development of specific immunity is a more accurate 
indicator of an effective immune response from treatment.  Therefore, 
serum was collected from treated guinea pigs and anti-HBs were 
measured by ELISA over time.  Results, Figure 17, show significant 
increases in antibody expression by week 3 and those responses 
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remain significantly increased through week 24.  The results are 
represented as GMT with IO groups having a peak GMT of 1000 and 
MEA EP at 5000 (Figure 17).  The peak fold increase of MEA EP over IO 
was 6.5 at week 18.  However, the fold increase remained relatively 
constant at about 5 for all time points. The titers measured do 
correlate with titers conferring protection [22, 41, 51, 119, 120].  
Statistical analysis was performed using student t-test and bonferroni 
correction to correct for multiple timepoints.  Error is represented as 
standard error of the means. 
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Discussion 
 
The data presented in this dissertation reflect that the MEA can 
be an effective mediator of gene expression, inflammation, and 
humoral immunity and that those responses are highly dependent on 
the electric field used in both mice and guinea pigs.  DNA vaccination 
is advantageous because it does not integrate into the host DNA, it is 
cost effective to produce and easily stored, it can be highly specific for 
tissue and/or cell type and can be made to vaccinate against multiple 
agents simultaneously.  The skin is an ideal target for DNA vaccination 
due to the large surface area and presence of antigen presenting cells 
like langerhan’s and dermal dendritic cells, specialized for induction of 
immunity [98]. 
However, injection of plasmid alone does not induce high enough 
immune responses to be protective.  EP is one method that has been 
shown to increase both plasmid expression as well as immunity.  
Previous EP methods have involved painful penetrating electrodes that 
go into the muscle to facilitate delivery.  Further advancements have 
been made using non-penetrating electrodes such as caliper and plate 
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electrodes.  However, these electrodes require high voltages to 
enhance delivery and therefore can cause tissue damage.   
Our initial experiments in mice evaluated the gene expression 
from intradermal delivery with either the MEA at various field strengths 
or the optimized 4PE at 100Vcm.  The data (Figure 3) showed that 
while gene expression with the 4PE represented the highest expression 
of luciferase the MEA could increase luciferase expression above IO 
and that by increasing the electric field could be made similar to the 
4PE in mice.  MEA EP conditions above 200V/cm were originally tested 
but resulted in visual damage of the skin.  The goal of this dissertation 
was to determine the effectiveness of this method for use in DNA 
vaccination; therefore, visual tissue damage is not considered an 
acceptable side effect.  Therefore only those conditions resulting in no 
visual damage were used in the rest of the studies (conditions of 
175V/cm or less).  Previously published results in rats demonstrated 
that at higher electric fields of 250V/cm the MEA could actually result 
in higher gene expression than the 4PE [21] and this was later also 
demonstrated in guinea pigs [55].  The differences in gene expression 
with the MEA and 4PE between these animal models is most likely 
related to skin thickness and structure of the two larger rodent 
models.  Both of these animals have thicker skin than mice and 
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therefore can be more easily injected into the dermis as well as having 
a more substantial network of cells for expression.   
Upon evaluating the effect of the MEA on damage and 
inflammation in mice, we were able to determine that EP with the MEA 
did induce inflammation and cellular recruitment when injected with 
plasmid DNA.  Edema was also seen but it was not isolated to EP 
delivered animals and is most likely an injection effect.  The cellular 
infiltrate seen at 48 hours after treatment is most likely not from a 
specific response to antigen.  Rather it is an effect from MEA EP.  This 
is a benefit to using EP as the delivery method for DNA vaccination.  It 
has previously been shown, and this data supports the idea that EP 
has an adjuvant effect. 
While overall gene expression is an important factor for 
determining electrodes and electric fields another important 
consideration is where the plasmid DNA is being expressed.  Are there 
a large number of cells with a low copy number of plasmid or are there 
a few cells with high copy numbers?  We proposed to answer this 
question by injecting with GFP and looking at GFP expression at 24 
and 48 hours after treatment (Figure 5).  IO was used as a control and 
we evaluated high and low electric fields, based on luciferase 
expression, using the MEA.  We were able to determine that 
expression was low at 24 hours but could be seen in the EP samples 
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(both 125 and 175V/cm).  However, at 48 hours GFP expression can 
be seen in the IO samples.  MEA EP with 125v/cm appears to still have 
higher expression and that expression is seen throughout the 
epidermis and to some extent in the dermis.  MEA EP with 175V/cm 
showed fewer cells expressing GFP than either IO or MEA EP at 
125V/cm and that most of the expression was within the dermis.  
Based on the luciferase expression in Figure 3, we show that the total 
expression with MEA EP at 175V/cm is approximately two fold higher 
than with 150V/cm.  It would stand to reason, given the trend of 
increasing gene expression with increasing electric field, that 125V/cm 
would demonstrate even lower expression levels than 150V/cm.  The 
difference between these groups may be the number of cells 
transfected, Figure 5.  When using higher electric fields more cells are 
killed during treatment and therefore less cells can be transfected, but 
those cells that survive are more greatly “porated” and can allow a 
greater amount of DNA into the surviving cells.  In the case of the 
lower electric field, less DNA can be taken up into the cells but more 
cells are moderately porated.  This results in a wider spread of DNA 
uptake and expression.  Increases in cellular infiltrate may also 
represent protective effects that are not represented by measurement 
of antibody responses and neutralizing activity.  Early work conducted 
with the gene gun was also suggestive of this effect [99, 100]. In that 
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study, toxin neutralization was quite low and in several cases non-
existent; however, several of these animals were protected in lethal 
challenge assay.  The question remains, which of these conditions is 
more important in regards to DNA vaccination?  This was the goal in 
Aim 2; to evaluate what vaccinations conditions resulted in the highest 
levels of humoral immunity.   
To evaluate the development of humoral immunity against a 
clinically relevant infectious agent we used B. anthracis as a model.  
While B. anthracis has a currently available vaccine it is not used for 
the general population due to the side effects as well as the heavy 
initial inoculation schedule.  The goal with development of new 
vaccines for B. anthracis is to reduce the production burden, side 
effects, and the number of initial inoculations necessary for 
vaccination.  It also has a well-studied small rodent model in the mice, 
as well as highly correlated in vitro assays of protection.  We received 
two plasmids from Hahn et al to study the development of DNA 
vaccination with the MEA.  These plasmids expressed the full length PA 
protein in commercially available backbones from Invitrogen.  These 
backbones consisted of either a secretion sequence (pSecTag2B) or a 
sequence targeting the endoplasmic reticulum to generate a 
membrane bound form of the protein (pCMVER).  Once the plasmids 
had been purified (Figure 7), we evaluated expression in vitro and in 
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vivo.  Both plasmids performed as expected.  In vitro, expression of PA 
from pCMVER/PA was found primarily in the lysate, whereas 
expression from pSecTagPA increased expression in supernatant about 
two fold.  In vivo injection of both plasmids individually resulted in the 
development of anti-PA antibodies when delivered by EP with the MEA.  
Total antibody production was highest with pCMVER/PA but was not 
seen until week 6.  Total antibody production from electrically 
mediated pSecTagPA was seen at early timepoints but had waned by 
week 9 and did not reach as high levels as pCMVER/PA.  We combined 
the two plasmids in a 1:1 ratio (pPA) to determine if this would 
generate a combination of these two responses.  The result was both 
an early and high antibody response that lasted at least 12 weeks 
providing the benefit of both plasmids.  This information supported the 
stated report by Hahn et al 2004 [99]. 
How does EP with the MEA compare to other electrode devices 
for the development of humoral immunity?  Muscle EP has been 
demonstrated to induce high levels of humoral immunity due to the 
long lasting expression of protein in the muscle.  However, it is not 
naturally an immune generating system.  The skin, however, is an 
ideal target for DNA vaccination.  We evaluated our 4 needle muscle 
electrode, with the MEA, and the 4PE to determine how well the MEA 
can induce humoral immunity.  Our results generated equal responses 
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at early timepoints regardless of electrode used.  However, at week 6, 
antibodies from skin EP devices had increased slightly above muscle 
EP.  EP with the 4PE began to decrease by week 9, at which time the 
muscle EP peaked above both skin electrodes.  EP with the MEA 
steadily increased even through week 12 when muscle EP began to 
decrease.  Three interesting points should be mentioned.  First, 
differences were seen in the IO groups.  Skin IO responses were seen 
as early as week 3, whereas muscle took until week 6 to develop.  This 
supports the immune stimulating idea of using the skin.  Second, even 
though when the 4PE generated higher luciferase gene expression 
compared to the MEA, this was not seen when evaluating antibody 
responses which showed that delivery with the MEA generated higher 
responses.  Therefore, based on these results, the MEA is a superior 
electrode as compared to the 4PE for stimulating immune responses.  
Finally, EP with the MEA generates similar immune responses as 
muscle EP over time and may maintain that immunity over longer 
periods of time.   
Our initial studies were very promising, so we set out to 
determine the optimal delivery parameters for development of 
humoral immunity using the MEA.  The three parameters we evaluated 
were amount of plasmid, treatment course, and electric field.  Only 
small differences were seen in varying the amount of plasmid, and 
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none of these differences were significant.  However, we could see 
small increases from increasing the amount of plasmid, but we 
deemed this irrelevant as injection with 200µg was the highest at 
weeks 3 and 6.  Similar results were seen with the treatment course, 
either a two treatment course at Days 0 or 14 or a three treatment 
course at Day 0, 14, and 28 were evaluated.  While there were only 
small differences seen between these two treatments it did appear 
that the three treatment condition started to decrease antibodies 
earlier than the two treatments.  This may be able to be explained by 
plasmid clearance.  It was reported that too much plasmid in the skin 
can result in faster clearance of the plasmid [101].  If this is the case 
then development of humoral immunity could be even more limited by 
a decrease in the time of expression from over treatment.  As noted in 
our other experiments the two treatment course appears to still be 
increasing at week 12.  Finally, evaluating the effect of electric field on 
development of humoral immunity resulted in significant differences.  
At all timepoints MEA EP with 125V/cm demonstrated the highest 
levels of antibody production.  This may be explained by the GFP data 
presented earlier in this dissertation where a larger area was 
expressing plasmid than in the higher EP conditions.  Interestingly, 
125V/cm demonstrated significantly increased responses as compared 
to all lower conditions at weeks 9 and 12 making it the optimal MEA EP 
80 
 
condition for the development of humoral immunity against B. 
anthracis.  However, conditions as high as 175V/cm can be used and 
demonstrate significant increases as compared to IO and EP conditions 
lower than 125V/cm as well thought 125V/cm is slightly higher they 
are not significantly different from one another. 
Additionally, when conducting our neutralizing assays, those 
animals that did not elicit 50% protection, and were therefore not 
considered protected, did still demonstrate some protective effects at 
20-40%.  This was not seen in the IO or backbone controls where at 
least 95% cell killing occurred.  Despite not being enough protection to 
be considered “protected”, there was some response in every MEA 
treated animal at 175 and 125V/cm.  
Our results compare favorably to most other published DNA 
vaccines in the Balb/c model [99, 102-106].  Those studies reporter 
higher total IgG in Balb/c mice required additional boosters, addition of 
recombinant protein boosts, [107, 108] or the use of signaling 
adjuvants.  Studies conducted in other mouse models have shown 
antibody responses that exceeded our results [40, 45, 100, 109, 110].  
This may be explained by differences in the immunogenicity of the 
models.  Balb/c mice are not highly susceptible to challenge from non-
encapsulated toxigenic strains of B. anthracis, whereas mouse models 
like A/J mice are highly susceptible [111].  In one study, that used 
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both A/J and Balb/c mice evaluated the development of humoral 
immunity against B. anthracis was evaluated.  The A/J mice developed 
almost a ten-fold higher response than the Balb/c mice [100].   
Our results compare favorably to muscle EP as well.  Two other 
studies, one in mice [45] and one in non-human primates [93], have 
been conducted specifically evaluating the use of EP to deliver a B. 
anthracis vaccine.  Our results are similar to the mouse study 
demonstrating approximately 25000 titers and peaking at similar time 
points between 6-9 weeks.  While our study required additional DNA, 
the use of the non-invasive MEA provides a positive advancement to 
this study.  The NHP experiment was conducted with penetrating 
needle electrodes into the muscle.  Their results showed the 
development of protective immune response [93].  While it would be 
difficult to compare our results to these, we feel that their data 
corroborate the claim that EP could be an effective delivery method for 
DNA vaccination against B. anthracis.  We believe our method may be 
a way of making this treatment even more tolerable and reducing the 
invasiveness. 
In aim 3 we evaluated the effect of using the MEA for DNA 
vaccination in a human-like skin model.  EP with the MEA generated 
increased plasmid expression as well as an increase in immune 
infiltrate after treatment.  The magnitude of immune infiltrate was 
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greater in EP groups than IO and there was minimal to no skin damage 
associated.  Specific, lasting, and significant levels of antibodies were 
greater than IO.  This is the first report to demonstrate the use of the 
MEA for DNA vaccination in a human-like skin model. 
As expected from our previous publication [55], EP with the MEA 
enhanced expression.  While the exact mechanism involved in EP 
remains unknown, increased plasmid expression at least in the case of 
DNA vaccination, plays an important role in recognition by the immune 
system [112].  EP has been shown to have an adjuvant effect by 
recruiting immune cells to the site of pulse application [2].  In our 
study, we saw an influx of nucleated cells from EP treated samples, 
shown in figure 14.  These cells are most likely neutrophils and 
macrophages based on morphology.  This is most likely a combination 
of both an EP mediated adjuvant effect and increased plasmid 
expression.  The induction of macrophages and polymorpho-nucleated 
neutrophils is indicative of a chronic inflammatory response.  While the 
perception of prolonged inflammation is typically negative, in our case 
it indicates that the expression of the plasmid is present for a 
prolonged period of time, giving the immune response enough time to 
perform its function.  Based on our earlier work, we would expect this 
prolonged expression to decrease after approximately 14 days, 
therefore allowing the body to heal and not generate deleterious 
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effects from inflammation [1, 55].  As shown in Figure 15, we can see 
that any visual effects from EP inflammation have recovered by Day 7. 
These findings seem to correlate with our antibody data, where 
an increase in the presence of specific antibodies was measured over 
time.  These antibodies were significantly increased as compared to 
injection only.  GMT’s ranged from 4000-16000 peaking at week 18.  
Antibody levels remained elevated until dropping off after week 21, but 
still remained increased as compared to injection only.  The enhanced 
intensity of humoral immunity by EP with the MEA corresponds to 
previously published skin EP results [113-116].  One of the primary 
reasons for evaluating our delivery method with HBV was because it is 
a well characterized vaccination model.  Published studies have 
reported geometric mean titers in conjunction with protective efficacy 
in guinea pigs.  While the presented GMT’s in these papers were higher 
than ours, they also reported protective levels more than 100 fold 
above the necessary levels of 10mIU/ml.  Our GMT’s are likely to still 
be within the protective range without generating unnecessary 
additional responses [117, 118].  Compared specifically to HBV DNA 
vaccines delivered by EP several animal models have been evaluated 
and EP has been shown to have protective levels from 10-1000mIU/ml 
[22, 41, 51, 119, 120].  The most recent comparable publication 
evaluated a minimally invasive device for protective vaccination 
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against influenza [120].  While their results were only presented as 
neutralizing titers against flu and cannot be compared directly we 
believe that our electrode design generates immune responses of 
equal quality without tissue penetration. 
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Conclusions 
 In this study we evaluated the use of the MEA for increased gene 
expression, inflammation, damage and the induction of humoral 
immunity.  These criteria were evaluated in two infectious models as 
well as two animal models.  Our initial results in the mouse 
demonstrated that gene expression could be enhanced in mice with 
increasing electric fields with the MEA and the highest field that could 
be used without visual tissue damage was 175V/cm.  Additionally, 
differences were seen in GFP expression based on the electric field 
applied.  Lower electric fields, which correlated to lower total luciferase 
expression, showed a slight increase in the number of cells transfected 
as compared to higher electric fields (higher total luciferase expression 
but less total cells transfected).  Inflammation was also noted in the 
mouse model as early as 48 hours after injection and EP. 
 In our mouse model against B. anthracis we were able to 
determine that plasmid dose and number of treatments played only a 
small role in development of humoral immunity.  Of the factors we 
studied, the most important was the electric field.  Electric fields 
ranging from 125-175V/cm showed significant increases in humoral 
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immunity as compared to lower and IO conditions.  They also 
correlated to 40-60% protection in our in vitro toxin neutralization 
assay. 
 Finally, in our guinea pig skin model against HBV we 
demonstrated that the MEA would effectively mediate increases in 
humoral immunity in the human like skin model.  Our results showed 
increased gene expression, inflammation, and significant increases in 
humoral immunity at all time-points through 6 months as compared to 
IO.  Slight redness was seen after treatment with the injection and 
MEA EP but was not greater than IO after 24 hours and was 
completely recovered by Day 7.   
 In conclusion, using the MEA for EP delivery effectively increases 
gene expression, immune cell infiltrates and humoral immunity in both 
mice and the human like skin model, guinea pig and therefore should 
continued to be utilized for DNA vaccine studies. 
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Future Directions 
 The MEA should continue to be evaluated for use in DNA 
vaccination against other clinically relevant infections.  There are 
several areas that could be studied to more completely evaluate the 
effect of MEA mediated EP.  First, we evaluated the induction of CMI 
since EP has been shown to enhance this type of immunity.  Based on 
our results showing cellular infiltrate the MEA is likely having an effect 
on cell mediate immunity as well.  Specifically, induction of CD4+ and 
CD8+ T cells should be evaluated.   
 Secondly, the addition of adjuvants could enhance the immune 
response and may provide greater longer lasting protection.  Recently, 
plasmid based cytokine adjuvants like IL-15, IL-2, and IL-12 have 
been used to enhance immunity.  The appropriate adjuvant would be 
dependent on the infectious model, whether humoral or cell mediated 
immunity was important to adjuvant.  Alternatively, the use of cell 
specific promoters could isolate DNA uptake.    Our studied utilized the 
MEA to the skin to theoretically increase DNA uptake by antigen 
presenting cells, but using a promoter that would isolate DNA uptake 
and gene expression to APC’s or more specifically dendritic cells for 
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example would increase antigen presentation and may increase 
immunogenicity. 
 Finally, a benefit of DNA vaccination is that the DNA can be 
made to encode for as many or as few components as necessary.  In 
the case of development of a MEA mediated DNA vaccine against B. 
anthracis plasmid addition of spore components with the toxin 
component may provide greater protection during an actually 
inhalational infection by providing immunity long before toxin 
production.  Alternatively, more highly optimized plasmids expressing 
smaller portions of PA (namely the binding epitope domain IV of PA).  
Using only very specific regions of PA would eliminate excess antibody 
production to generate only those antibodies that would inhibit toxin 
formation and enhance protection. 
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Appendix B:  License Permissions for Reprint  
 
Creative Commons License 
Attribution 3.0 Unported 
 
CREATIVE COMMONS CORPORATION IS NOT A LAW FIRM AND DOES 
NOT PROVIDE LEGAL SERVICES. DISTRIBUTION OF THIS LICENSE 
DOES NOT CREATE AN ATTORNEY-CLIENT RELATIONSHIP. CREATIVE 
COMMONS PROVIDES THIS INFORMATION ON AN "AS-IS" BASIS. 
CREATIVE COMMONS MAKES NO WARRANTIES REGARDING THE 
INFORMATION PROVIDED, AND DISCLAIMS LIABILITY FOR DAMAGES 
RESULTING FROM ITS USE.  
License 
THE WORK (AS DEFINED BELOW) IS PROVIDED UNDER THE TERMS 
OF THIS CREATIVE COMMONS PUBLIC LICENSE ("CCPL" OR 
"LICENSE"). THE WORK IS PROTECTED BY COPYRIGHT AND/OR 
OTHER APPLICABLE LAW. ANY USE OF THE WORK OTHER THAN AS 
AUTHORIZED UNDER THIS LICENSE OR COPYRIGHT LAW IS 
PROHIBITED. 
BY EXERCISING ANY RIGHTS TO THE WORK PROVIDED HERE, YOU 
ACCEPT AND AGREE TO BE BOUND BY THE TERMS OF THIS LICENSE. 
TO THE EXTENT THIS LICENSE MAY BE CONSIDERED TO BE A 
CONTRACT, THE LICENSOR GRANTS YOU THE RIGHTS CONTAINED 
HERE IN CONSIDERATION OF YOUR ACCEPTANCE OF SUCH TERMS 
AND CONDITIONS. 
 
1. Definitions 
a. "Adaptation" means a work based upon the Work, or upon the 
Work and other pre-existing works, such as a translation, 
adaptation, derivative work, arrangement of music or other 
alterations of a literary or artistic work, or phonogram or 
performance and includes cinematographic adaptations or any 
other form in which the Work may be recast, transformed, or 
adapted including in any form recognizably derived from the 
original, except that a work that constitutes a Collection will not 
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be considered an Adaptation for the purpose of this License. For 
the avoidance of doubt, where the Work is a musical work, 
performance or phonogram, the synchronization of the Work in 
timed-relation with a moving image ("synching") will be 
considered an Adaptation for the purpose of this License. 
b. "Collection" means a collection of literary or artistic works, 
such as encyclopedias and anthologies, or performances, 
phonograms or broadcasts, or other works or subject matter 
other than works listed in Section 1(f) below, which, by reason 
of the selection and arrangement of their contents, constitute 
intellectual creations, in which the Work is included in its entirety 
in unmodified form along with one or more other contributions, 
each constituting separate and independent works in 
themselves, which together are assembled into a collective 
whole. A work that constitutes a Collection will not be considered 
an Adaptation (as defined above) for the purposes of this 
License. 
c. "Distribute" means to make available to the public the original 
and copies of the Work or Adaptation, as appropriate, through 
sale or other transfer of ownership. 
d. "Licensor" means the individual, individuals, entity or entities 
that offer(s) the Work under the terms of this License. 
e. "Original Author" means, in the case of a literary or artistic 
work, the individual, individuals, entity or entities who created 
the Work or if no individual or entity can be identified, the 
publisher; and in addition (i) in the case of a performance the 
actors, singers, musicians, dancers, and other persons who act, 
sing, deliver, declaim, play in, interpret or otherwise perform 
literary or artistic works or expressions of folklore; (ii) in the 
case of a phonogram the producer being the person or legal 
entity who first fixes the sounds of a performance or other 
sounds; and, (iii) in the case of broadcasts, the organization that 
transmits the broadcast. 
f. "Work" means the literary and/or artistic work offered under 
the terms of this License including without limitation any 
production in the literary, scientific and artistic domain, whatever 
may be the mode or form of its expression including digital form, 
such as a book, pamphlet and other writing; a lecture, address, 
sermon or other work of the same nature; a dramatic or 
dramatico-musical work; a choreographic work or entertainment 
in dumb show; a musical composition with or without words; a 
cinematographic work to which are assimilated works expressed 
by a process analogous to cinematography; a work of drawing, 
painting, architecture, sculpture, engraving or lithography; a 
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photographic work to which are assimilated works expressed by 
a process analogous to photography; a work of applied art; an 
illustration, map, plan, sketch or three-dimensional work relative 
to geography, topography, architecture or science; a 
performance; a broadcast; a phonogram; a compilation of data 
to the extent it is protected as a copyrightable work; or a work 
performed by a variety or circus performer to the extent it is not 
otherwise considered a literary or artistic work. 
g. "You" means an individual or entity exercising rights under this 
License who has not previously violated the terms of this License 
with respect to the Work, or who has received express 
permission from the Licensor to exercise rights under this 
License despite a previous violation. 
h. "Publicly Perform" means to perform public recitations of the 
Work and to communicate to the public those public recitations, 
by any means or process, including by wire or wireless means or 
public digital performances; to make available to the public 
Works in such a way that members of the public may access 
these Works from a place and at a place individually chosen by 
them; to perform the Work to the public by any means or 
process and the communication to the public of the 
performances of the Work, including by public digital 
performance; to broadcast and rebroadcast the Work by any 
means including signs, sounds or images. 
i. "Reproduce" means to make copies of the Work by any means 
including without limitation by sound or visual recordings and the 
right of fixation and reproducing fixations of the Work, including 
storage of a protected performance or phonogram in digital form 
or other electronic medium. 
 
2. Fair Dealing Rights. Nothing in this License is intended to reduce, 
limit, or restrict any uses free from copyright or rights arising from 
limitations or exceptions that are provided for in connection with the 
copyright protection under copyright law or other applicable laws. 
 
3. License Grant. Subject to the terms and conditions of this License, 
Licensor hereby grants You a worldwide, royalty-free, non-exclusive, 
perpetual (for the duration of the applicable copyright) license to 
exercise the rights in the Work as stated below: 
a. to Reproduce the Work, to incorporate the Work into one or 
more Collections, and to Reproduce the Work as incorporated in 
the Collections; 
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b. to create and Reproduce Adaptations provided that any such 
Adaptation, including any translation in any medium, takes 
reasonable steps to clearly label, demarcate or otherwise identify 
that changes were made to the original Work. For example, a 
translation could be marked "The original work was translated 
from English to Spanish," or a modification could indicate "The 
original work has been modified."; 
c. to Distribute and Publicly Perform the Work including as 
incorporated in Collections; and, 
d. to Distribute and Publicly Perform Adaptations. 
e. For the avoidance of doubt: 
i. Non-waivable Compulsory License Schemes. In those 
jurisdictions in which the right to collect royalties through 
any statutory or compulsory licensing scheme cannot be 
waived, the Licensor reserves the exclusive right to collect 
such royalties for any exercise by You of the rights granted 
under this License; 
ii. Waivable Compulsory License Schemes. In those 
jurisdictions in which the right to collect royalties through 
any statutory or compulsory licensing scheme can be 
waived, the Licensor waives the exclusive right to collect 
such royalties for any exercise by You of the rights granted 
under this License; and, 
iii. Voluntary License Schemes. The Licensor waives the 
right to collect royalties, whether individually or, in the 
event that the Licensor is a member of a collecting society 
that administers voluntary licensing schemes, via that 
society, from any exercise by You of the rights granted 
under this License. 
The above rights may be exercised in all media and formats whether 
now known or hereafter devised. The above rights include the right to 
make such modifications as are technically necessary to exercise the 
rights in other media and formats. Subject to Section 8(f), all rights 
not expressly granted by Licensor are hereby reserved. 
 
4. Restrictions. The license granted in Section 3 above is expressly 
made subject to and limited by the following restrictions: 
a. You may Distribute or Publicly Perform the Work only under the 
terms of this License. You must include a copy of, or the Uniform 
Resource Identifier (URI) for, this License with every copy of the 
Work You Distribute or Publicly Perform. You may not offer or 
impose any terms on the Work that restrict the terms of this 
License or the ability of the recipient of the Work to exercise the 
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rights granted to that recipient under the terms of the License. 
You may not sublicense the Work. You must keep intact all 
notices that refer to this License and to the disclaimer of 
warranties with every copy of the Work You Distribute or Publicly 
Perform. When You Distribute or Publicly Perform the Work, You 
may not impose any effective technological measures on the 
Work that restrict the ability of a recipient of the Work from You 
to exercise the rights granted to that recipient under the terms 
of the License. This Section 4(a) applies to the Work as 
incorporated in a Collection, but this does not require the 
Collection apart from the Work itself to be made subject to the 
terms of this License. If You create a Collection, upon notice 
from any Licensor You must, to the extent practicable, remove 
from the Collection any credit as required by Section 4(b), as 
requested. If You create an Adaptation, upon notice from any 
Licensor You must, to the extent practicable, remove from the 
Adaptation any credit as required by Section 4(b), as requested. 
b. If You Distribute, or Publicly Perform the Work or any 
Adaptations or Collections, You must, unless a request has been 
made pursuant to Section 4(a), keep intact all copyright notices 
for the Work and provide, reasonable to the medium or means 
You are utilizing: (i) the name of the Original Author (or 
pseudonym, if applicable) if supplied, and/or if the Original 
Author and/or Licensor designate another party or parties (e.g., 
a sponsor institute, publishing entity, journal) for attribution 
("Attribution Parties") in Licensor's copyright notice, terms of 
service or by other reasonable means, the name of such party or 
parties; (ii) the title of the Work if supplied; (iii) to the extent 
reasonably practicable, the URI, if any, that Licensor specifies to 
be associated with the Work, unless such URI does not refer to 
the copyright notice or licensing information for the Work; and 
(iv) , consistent with Section 3(b), in the case of an Adaptation, 
a credit identifying the use of the Work in the Adaptation (e.g., 
"French translation of the Work by Original Author," or 
"Screenplay based on original Work by Original Author"). The 
credit required by this Section 4 (b) may be implemented in any 
reasonable manner; provided, however, that in the case of a 
Adaptation or Collection, at a minimum such credit will appear, if 
a credit for all contributing authors of the Adaptation or 
Collection appears, then as part of these credits and in a manner 
at least as prominent as the credits for the other contributing 
authors. For the avoidance of doubt, You may only use the credit 
required by this Section for the purpose of attribution in the 
manner set out above and, by exercising Your rights under this 
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License, You may not implicitly or explicitly assert or imply any 
connection with, sponsorship or endorsement by the Original 
Author, Licensor and/or Attribution Parties, as appropriate, of 
You or Your use of the Work, without the separate, express prior 
written permission of the Original Author, Licensor and/or 
Attribution Parties. 
c. Except as otherwise agreed in writing by the Licensor or as may 
be otherwise permitted by applicable law, if You Reproduce, 
Distribute or Publicly Perform the Work either by itself or as part 
of any Adaptations or Collections, You must not distort, mutilate, 
modify or take other derogatory action in relation to the Work 
which would be prejudicial to the Original Author's honor or 
reputation. Licensor agrees that in those jurisdictions (e.g. 
Japan), in which any exercise of the right granted in Section 3(b) 
of this License (the right to make Adaptations) would be deemed 
to be a distortion, mutilation, modification or other derogatory 
action prejudicial to the Original Author's honor and reputation, 
the Licensor will waive or not assert, as appropriate, this 
Section, to the fullest extent permitted by the applicable national 
law, to enable You to reasonably exercise Your right under 
Section 3(b) of this License (right to make Adaptations) but not 
otherwise. 
 
5. Representations, Warranties and Disclaimer 
UNLESS OTHERWISE MUTUALLY AGREED TO BY THE PARTIES IN 
WRITING, LICENSOR OFFERS THE WORK AS-IS AND MAKES NO 
REPRESENTATIONS OR WARRANTIES OF ANY KIND CONCERNING THE 
WORK, EXPRESS, IMPLIED, STATUTORY OR OTHERWISE, INCLUDING, 
WITHOUT LIMITATION, WARRANTIES OF TITLE, MERCHANTIBILITY, 
FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT, OR THE 
ABSENCE OF LATENT OR OTHER DEFECTS, ACCURACY, OR THE 
PRESENCE OF ABSENCE OF ERRORS, WHETHER OR NOT 
DISCOVERABLE. SOME JURISDICTIONS DO NOT ALLOW THE 
EXCLUSION OF IMPLIED WARRANTIES, SO SUCH EXCLUSION MAY 
NOT APPLY TO YOU. 
 
6. Limitation on Liability. EXCEPT TO THE EXTENT REQUIRED BY 
APPLICABLE LAW, IN NO EVENT WILL LICENSOR BE LIABLE TO YOU 
ON ANY LEGAL THEORY FOR ANY SPECIAL, INCIDENTAL, 
CONSEQUENTIAL, PUNITIVE OR EXEMPLARY DAMAGES ARISING OUT 
OF THIS LICENSE OR THE USE OF THE WORK, EVEN IF LICENSOR HAS 
BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. 
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7. Termination 
a. This License and the rights granted hereunder will terminate 
automatically upon any breach by You of the terms of this 
License. Individuals or entities who have received Adaptations or 
Collections from You under this License, however, will not have 
their licenses terminated provided such individuals or entities 
remain in full compliance with those licenses. Sections 1, 2, 5, 6, 
7, and 8 will survive any termination of this License. 
b. Subject to the above terms and conditions, the license granted 
here is perpetual (for the duration of the applicable copyright in 
the Work). Notwithstanding the above, Licensor reserves the 
right to release the Work under different license terms or to stop 
distributing the Work at any time; provided, however that any 
such election will not serve to withdraw this License (or any 
other license that has been, or is required to be, granted under 
the terms of this License), and this License will continue in full 
force and effect unless terminated as stated above. 
 
8. Miscellaneous 
a. Each time You Distribute or Publicly Perform the Work or a 
Collection, the Licensor offers to the recipient a license to the 
Work on the same terms and conditions as the license granted to 
You under this License. 
b. Each time You Distribute or Publicly Perform an Adaptation, 
Licensor offers to the recipient a license to the original Work on 
the same terms and conditions as the license granted to You 
under this License. 
c. If any provision of this License is invalid or unenforceable under 
applicable law, it shall not affect the validity or enforceability of 
the remainder of the terms of this License, and without further 
action by the parties to this agreement, such provision shall be 
reformed to the minimum extent necessary to make such 
provision valid and enforceable. 
d. No term or provision of this License shall be deemed waived and 
no breach consented to unless such waiver or consent shall be in 
writing and signed by the party to be charged with such waiver 
or consent. 
e. This License constitutes the entire agreement between the 
parties with respect to the Work licensed here. There are no 
understandings, agreements or representations with respect to 
the Work not specified here. Licensor shall not be bound by any 
additional provisions that may appear in any communication 
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from You. This License may not be modified without the mutual 
written agreement of the Licensor and You. 
f. The rights granted under, and the subject matter referenced, in 
this License were drafted utilizing the terminology of the Berne 
Convention for the Protection of Literary and Artistic Works (as 
amended on September 28, 1979), the Rome Convention of 
1961, the WIPO Copyright Treaty of 1996, the WIPO 
Performances and Phonograms Treaty of 1996 and the Universal 
Copyright Convention (as revised on July 24, 1971). These rights 
and subject matter take effect in the relevant jurisdiction in 
which the License terms are sought to be enforced according to 
the corresponding provisions of the implementation of those 
treaty provisions in the applicable national law. If the standard 
suite of rights granted under applicable copyright law includes 
additional rights not granted under this License, such additional 
rights are deemed to be included in the License; this License is 
not intended to restrict the license of any rights under applicable 
law. 
Creative Commons Notice 
Creative Commons is not a party to this License, and makes no 
warranty whatsoever in connection with the Work. Creative Commons 
will not be liable to You or any party on any legal theory for any 
damages whatsoever, including without limitation any general, special, 
incidental or consequential damages arising in connection to this 
license. Notwithstanding the foregoing two (2) sentences, if Creative 
Commons has expressly identified itself as the Licensor hereunder, it 
shall have all rights and obligations of Licensor. 
Except for the limited purpose of indicating to the public that the Work 
is licensed under the CCPL, Creative Commons does not authorize the 
use by either party of the trademark "Creative Commons" or any 
related trademark or logo of Creative Commons without the prior 
written consent of Creative Commons. Any permitted use will be in 
compliance with Creative Commons' then-current trademark usage 
guidelines, as may be published on its website or otherwise made 
available upon request from time to time. For the avoidance of doubt, 
this trademark restriction does not form part of this License. 
Creative Commons may be contacted at http://creativecommons.org/. 
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Abstract 
Current progress in the development of vaccines has decreased 
the incidence of fatal and non-fatal infections and increased longevity.  
However, new technologies need to be developed to combat an 
emerging generation of infectious diseases.  DNA vaccination has been 
demonstrated to have great potential for use with a wide variety of 
diseases.  Alone, this technology does not generate a significant 
immune response for vaccination, but combined with delivery by 
electroporation (EP), can enhance plasmid expression and immunity.  
Most EP systems, while effective, can be invasive and painful making 
them less desirable for use in vaccination.  Our lab recently developed 
a non-invasive electrode known as the multi-electrode array (MEA), 
which lies flat on the surface of the skin without penetrating the tissue.  
In this study we evaluated the MEA for its use in DNA vaccination 
using Hepatitis B virus as the infectious model.  We utilized the guinea 
pig model because their skin is similar in thickness and morphology to 
humans.  The plasmid encoding Hepatitis B surface antigen (HBsAg) 
was delivered intradermally with the MEA to guinea pig skin.  The 
results show increased protein expression resulting from plasmid 
delivery using the MEA as compared to injection alone.  Within 48 
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hours of treatment, there was an influx of cellular infiltrate in 
experimental groups.  Humoral responses were also increased 
significantly in both duration and intensity as compared to injection 
only groups.  While this electrode requires further study, our results 
suggest that the MEA has potential for use in electrically mediated 
intradermal DNA vaccination. 
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Introduction 
The development of vaccines is widely considered to be one of 
the most important medical advancements of the 20th century.  
Current methods have been pushed to the limits of their potential.  
New techniques need to be developed and employed to combat a new 
generation of diseases and infections.  There are several advantages 
to DNA vaccination.  DNA vaccines are cost effective to produce, they 
can be easily stored, they are highly specific and their multivalent 
nature means that they could be combined to vaccinate against 
several different components simultaneously [1-3].  Either due to low 
expression or lack of immune recognition, injection of plasmid DNA 
alone does not elicit a strong enough immune response for protective 
vaccination.  Electroporation (EP) is a non viral plasmid DNA delivery 
approach that effectively enhances plasmid expression [4, 5] and 
immunity [6-10].   
EP requires the application of electric fields causing 
permeabilization of the cell membranes.  The permeabilized membrane 
briefly contains “pores” that allow large molecules, like DNA, to enter 
the cell.  Initial studies evaluating in vivo EP for transgene delivery and 
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expression were performed on rat brain tumors [5] and rat livers [4].  
Those studies demonstrated enhanced delivery and expression of 
plasmid DNA from EP mediated delivery.  Successful EP mediated DNA 
delivery has been demonstrated in most tissue types and for several 
therapeutic and prophylactic indications such as cancer therapy, 
infectious diseases, wound healing, metabolic disorders and vaccines 
[11].  Recently several clinical trials have been initiated.  Two clinical 
trials have been completed using EP, one assessing tolerability of 
intramuscular delivery [12, 13] and the other assessing toxicity and 
clinical utility of delivering pIL-12 intratumorally by EP to melanoma 
patients [14].  The latter demonstrated the safety, minimal toxicity, 
and feasibility for the use of EP in the clinic [14].  Since the successful 
completion of these studies, 19 others are currently active or 
recruiting.  Five of those are involving DNA vaccination against 
infectious agents (clinicaltrials.gov; Keyword:  Electroporation).   
Initial in vivo EP DNA vaccine studies evaluated gene expression 
and immune stimulation from delivery of plasmids encoding either 
Hepatitis B Virus (HBV) protein or Human Immunodeficiency Virus 
(HIV) protein, gag, to the muscle.  Their results confirmed that 
increased humoral responses to HBV [6] and cellular [9] immune 
response to HIV gag from EP compared to injection only (IO) of 
plasmid DNA.  More recent studies have broadened the list of 
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pathogens which EP has been successfully used in vivo to include other 
viral pathogens such as: Simian Immunodeficiency Virus [15-18], 
Severe Acute Respiratory Syndrome [19, 20], Influenza [21-25], West 
Nile and Japanese Encephalitis [26, 27], as well as Hepatitis B and C 
[28-32] and Human Papilloma Virus [33, 34].  EP delivered DNA 
vaccines expressing proteins of the parasitic infection Plasmodium 
falciparum, one of the parasites causing malaria [35], as well as 
bacterial infections like Bacillus anthracis [36], Clostridium botulinum 
[37], and Mycobacterium tuberculosis [38] have also been 
demonstrated to enhance immunogenicity.  These results demonstrate 
the capacity of EP to enhance not only gene delivery and protein 
expression but also its ability to stimulate the host immune response 
against a wide variety of pathogens.   
Current electrically mediated DNA vaccines employ painful 
invasive needle electrodes that are inserted into the muscle for 
electrical stimulation.  The primary tissue used for in vivo EP is muscle 
because it is accessible, highly vascularized, multinucleated, and 
expresses DNA for long periods of time due to the post-mitotic nature 
of the tissue [39].  However, pain associated with administration is not 
desirable.  As such, alternative delivery sites and methods have been 
explored.  The skin is an attractive target for vaccination because of 
the high proportion of antigen presenting cells (APC) and large surface 
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area.  Recent studies, as well as work done in our laboratory, 
demonstrated that intradermal electrically mediated DNA expression 
can be increased both locally and systemically [8, 40-44].  Electrodes 
developed for skin EP include: caliper, plate, tweezer, and clip 
electrodes as well as several needle electrodes [14, 45-48]. 
To develop an electrically mediated intradermal DNA vaccine we 
utilized the non-invasive multi-electrode array (MEA), shown in figure 
1, for EP delivery.  The MEA has 16 electrodes placed 2mm apart and 
is arranged in 4 rows [45].  Pulses are administered in a sequence that 
utilizes 4 electrodes at a time, forming 2 X 2 mm squares (9 total 
squares).  Pulses are applied in pairs, in two directions, perpendicular 
to each other (18 pulses) for 4 rounds of pulsing (72 total pulses).  
While we have not as yet modeled or directly measured the fields 
generated across the treated area of skin, we believe by applying the 
field across a smaller area (2 X 2 mm) will facilitate obtaining a more 
uniform field then would be obtained when the field is applied across 
the entire treated area (6 X 6 mm).  Our lab previously demonstrated 
that this electrode, when used in a guinea pig skin model, could 
significantly increase reporter gene activity [45].  Conditions required 
for optimal expression were determined to be between 200-300 V/cm 
and 150ms.   
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An additional consideration for establishing a MEA delivered DNA 
vaccine is choosing the appropriate animal model.  Guinea pig skin is 
similar to human skin in thickness and morphology [49].  For this 
reason, we selected the guinea pig model to better evaluate our 
delivery approach utilizing a small animal model with skin similar to 
humans.  Therefore, the goal of this study was to evaluate intradermal 
MEA EP delivery of Hepatitis B surface antigen in a human-like skin 
model.   
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Methods 
2.1 Ethics Statement:  All animal procedures were conducted in a 
facility (USF) that is fully accredited by the Association for the 
Assessment and Accreditation of Laboratory Animal Care (AAALAC) 
and the Public Health Service (PHS).  Research was conducted under a 
protocol approved by the Institutional Animal Care and Use Committee 
(IACUC) at the University of South Florida, College of Medicine 
(protocol # 2879).  All animals were housed, handled and utilizing 
following guidelines of the United States National Institutes of Health. 
 
2.2 Animals: Female Hartley guinea pigs between 200-250g were used 
in this study to evaluate skin EP conditions.  Guinea pigs were housed 
at the University of South Florida, College of Medicine vivarium and 
were rested for one week prior to experimentation.  Guinea pigs were 
anesthetized with 2.5-3.0% isoflurane before and during all 
procedures.  No previous exposure to Hepatitis B virus was known.   
 
2.3 Plasmid:  The plasmid used in this study was gWiz™ HBsAg 
(Aldevron, Fargo, ND).  This plasmid encodes for the surface antigen 
of Hepatitis B and is driven by the CMV promoter.   
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2.4 Immunization: All guinea pigs were intradermally injected with 
100µg (2mg/ml) of gWiz™ HBsAg at two sites on the left flank.  MEA 
EP was performed at 300V/cm and 150ms and 72 pulses.  The two 
groups used in this study were control group injection of plasmid only 
(IO) and injection of plasmid plus EP (I +EP).  All groups were boosted 
with the same condition at Day 14. 
 
2.5 serum collection:  Guinea pigs were bled through the jugular vein 
at various time points from Day 0 through Day 168. Blood was 
collected and serum isolated in serum separator tubes.  Serum was 
diluted two-fold starting at 1:10. 
 
2.6 Tissue collection:  Guinea pigs were treated as described with 
gWiz™ HBsAg with and without EP.  Those guinea pigs whose tissue 
was collected for plasmid expression were sacrificed 48 hours after one 
treatment and skin samples were harvested by excising the treatment 
site and snap frozen.  Those guinea pigs whose tissue was collected to 
assess damage and cell infiltrate were treated and harvested 96 hours 
after one treatment and the tissue was snap frozen. 
 
2.7 Indirect ELISA for the detection of Hepatitis B surface antigen 
antibodies: The enzyme linked immunosorbant assay (ELISA) was 
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used to assess the production of antibodies from treatment and 
performed per manufacturer’s protocol (Aldevron).  Briefly, a 96-well 
plate (Nunc) was coated with 10µg/ml of Hepatitis B surface antigen 
(Aldevron) and allowed to coat overnight at 4°C.  The plate was 
blocked with 3% BSA in PBST for 2 hours at 37°C.  Serum samples 
were two-fold diluted in blocking buffer and added to the plate for 2 
hours at 37°C.  Goat anti-Guinea pig-AP antibody was added at a 
1:10000 dilution in blocking buffer.  AP substrate, pNPP, (Sigma) was 
added to colorize and the plate was read at 405nm. 
 
2.8 Immunohistochemistry: Pathological analysis of the skin sections 
was performed to determine the extent of plasmid expression as well 
as inflammation and tissue damage.  An anti-HBsAg was used to 
detect plasmid expression.  Skin samples taken 48 hours after 
treatment were frozen, sectioned, and placed on slides.  Slides were 
rehydrated and then blocked with 3% BSA in PBST and incubated in a 
humidifying chamber for 1 hr.  A HRP conjugated anti-HBsAg 
(AbDSerotec) was made in blocking buffer at a 1:200 dilution.  All 
samples were counterstained with Hematoxylin& Eosin.  Samples 
collected at 96 hours frozen, sectioned, and placed on slides were 
stained with H & E to determine the extent of cellular 
infiltrate/inflammation.   
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2.9 Statistical analysis:  All Guinea pigs were bled at Day 0 to 
determine background optical density (OD).  OD’s were averaged and 
2 standard deviations added to determine positive (0.1 OD).  
Experimental serum samples were diluted two-fold starting at 1:10.  
End point titers were calculated and plotted as Geometric Means.  
Significance was determined by student t-test using the bonferroni 
correction for multiple comparisons. 
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Results 
 
3.1 Plasmid expression from EP. 
The first step in evaluating the MEA for delivery of DNA vaccines 
in a human-like model was to determine the expression levels of 
gWiz™ HBsAg.  Guinea pigs were treated as described with or without 
EP using the MEA.  48 hours after delivery the guinea pigs were 
euthanized and the treated skin harvested and processed for 
histological evaluation.  Expression of HBsAg was determined by 
immunohistochemistry.  Expression of HBsAg is seen in IO and I+EP 
(Fig 1a and b), however increased staining was observed in the I+EP 
samples.  Expression is contained within the epidermis of IO animals.  
When compared to I+EP animals expression can be seen within the 
epidermis and dermis.     
 
3.2 Immune cell infiltrate and tissue damage 
To determine whether EP with the MEA would recruit immune 
cells to the treatment site and cause inflammation, guinea pigs were 
treated as described and tissue samples harvested 96 hours after 
treatment.  Samples were stained with H&E to assess cellular infiltrate, 
damage, and necrosis from treatment.  The induction of immune 
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stimulation is important for vaccines in general, but can be limited for 
DNA vaccines.  Induction of immune cell infiltrate was observed (Fig 2 
C-F 100X magnification).  Background levels, Fig 2c, of infiltrate are 
demonstrated in no treatment control and correspond to low levels of 
cellular infiltrate (purple).  IO samples show slight increases in 
infiltrate as compared to no treatment, Fig 2d.  In contrast, I+EP 
samples show a large increase in cellular infiltrate, Fig 2e.  I + EP 
groups contained primarily macrophages and multi-lobed cells, most 
likely activated neutrophils (200x magnification Fig. 2f), corresponding 
to a prolonged inflammatory immune response [50].   
Edema was seen in all samples except no treatment controls; 
and did not appear increased due to EP.  This is most likely a result 
from the injection of plasmid into the tissue.  In most samples tissue 
damage and necrosis were not seen.  However, two EP delivered 
samples had minimal ulcerations at 96 hours after treatment, one of 
which also had about 1% necrosis.  There were no other samples 
showing damage or necrosis (data not shown).  Gross evaluation of 
the skin shows no difference between IO and I+EP groups over time 
(Fig 3).  Complete visual recovery of the skin is seen by Day 7. 
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3.3 Anti-Hepatitis B surface antigen antibodies 
While cellular infiltrate can be an early indicator of immunity, a 
more accurate measure is the induction of specific antibodies 
generated against HBsAg.  Anti-HBs were measured by ELISA over 
time.  Guinea pigs, treated and serum collected as described in 
methods, showed significant increases in antibody expression from 
three weeks after initial treatment through week 24.  The data 
collected was from 3 independent experiments (n=6 for each 
experiement) with a total n of 18 for both IO and EP groups.  Peak 
expression for both groups occurred at week 18 with IO groups having 
a GMT of 1000 and I+EP animals at 5000 (Fig 4).  The fold increase 
over IO remained relatively constant at about 5 fold with the greatest 
fold increase over IO of 6.5 occurring at week 18. 
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Discussion 
These data demonstrate that the MEA can be effective for the 
use in electrically mediated DNA vaccination in a human-like skin 
model.  EP with the MEA generated increased plasmid expression as 
well as an increase in immune infiltrate after treatment.  The 
magnitude of immune infiltrate was greater in EP groups than IO and 
there was minimal to no skin damage associated.  Specific, lasting, 
and significant levels of antibodies were greater than IO.  This is the 
first report to demonstrate the use of the MEA for DNA vaccination in a 
human-like skin model. 
DNA vaccination is advantageous because it does not integrate 
into the host DNA, it is cost effective to produce and easily stored, it 
can be highly specific for tissue and/or cell type and can be made to 
vaccinate against multiple agents simultaneously.  The skin is an ideal 
target for DNA vaccination due to the large surface area and presence 
of antigen presenting cells like langerhan’s and dermal dendritic cells, 
specialized for induction of immunity [51].  However, injection of 
plasmid alone does not induce high enough immune responses to be 
protective.  EP is one method that has been shown to increase both 
plasmid expression as well as immunity.   
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Previous EP methods have involved painful penetrating 
electrodes that go into the muscle to facilitate delivery.  Further 
advancements have been made using non-penetrating electrodes such 
as caliper and plate electrodes.  However, these electrodes require 
high voltages to enhance delivery and therefore can cause tissue 
damage.  In this study, we have evaluated a non-penetrating electrode 
which reduces the gap width between electrodes to 2mm thereby 
reducing the absolute voltage applied and preventing visible tissue 
damage while still increasing plasmid expression and immunity. 
As expected from our previous publication [45], EP with the MEA 
enhanced expression.  While the exact reason for the effectiveness of 
EP remains unknown, increased plasmid expression at least in the case 
of DNA vaccination, plays an important role in recognition by the 
immune system [52].  EP has been shown to have an adjuvant effect 
by recruiting immune cells to the site of pulse application [53].  In our 
study, we saw an influx of nucleated cells from EP treated samples.  
These cells are most likely neutrophils and macrophages based on 
morphology.  This is most likely a combination of both an EP mediated 
adjuvant effect and increased plasmid expression.  The induction of 
macrophages and polymorpho-nucleated neutrophils is indicative of a 
chronic inflammatory response.  While the perception of prolonged 
inflammation is typically negative in our case it indicates that the 
137 
 
expression of the plasmid is present for a prolonged period of time, 
giving the immune response enough time to perform its function.  
Based on our earlier work [45] we would expect this prolonged 
expression to decrease after approximately 14 days, therefore allowing 
the body to heal and not generate deleterious effects from 
inflammation.   
These findings seem to correlate with our antibody data, where 
an increase in the presence of specific antibodies was measured over 
time.  These antibodies were significantly increased as compared to 
injection only.  Geometric mean titers ranged from 4000-16000 
peaking at week 18.  Antibody levels remained elevated until dropping 
off after week 21, but still remained increased as compared to 
injection only.  The enhanced intensity of humoral immunity by EP 
with the MEA corresponds to previously published skin EP results [54-
57].  One of the primary reasons for evaluating our delivery method 
with Hepatitis B was because it is a well characterized vaccination 
model.  Published studies have reported geometric mean titers in 
conjunction with protective efficacy in guinea pigs.  While the 
presented GMT’s in these papers were higher than ours, they also 
reported protective levels more than 100 fold above the necessary 
levels.  Our GMT’s are likely to still be within the protective range 
without generating unnecessary additional responses [58, 59].  
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Comparing specifically to Hepatitis B DNA vaccines delivered by EP 
several animal models have been evaluated and EP has been shown to 
have protective levels from 10-1000mIU/ml [6, 9, 32, 60, 61].  The 
most recent comparable publication evaluated a minimally invasive 
device for protective vaccination against influenza [62].  While their 
results were only presented as neutralizing titers against flu and 
cannot be compared directly we believe that our electrode design 
generates immune responses of equal quality without tissue 
penetration. 
The data represented here demonstrate the capability of the 
MEA to increase plasmid expression, immune cell infiltrate and 
inflammatory response, as well as antibody production over 24 weeks 
in a human-like skin model.  This information presents a potential new 
method for DNA vaccination that may be translatable to humans.  
Further studies will examine the MEA for use in DNA vaccination 
against other infectious agents. 
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Figure legends 
Fig. 1 Non-invasive Multi-Electrode Array.  The MEA has 16 electrodes 
placed 2mm apart and is arranged in 4 rows.  Pulses are administered 
in a sequence that utilizes 4 electrodes at a time, forming 2 X 2 mm 
squares (9 total squares).  Pulses are applied in pairs, in two 
directions, perpendicular to each other (18 pulses) for 4 rounds of 
pulsing (72 total pulses).  This image is reprinted from The Journal of 
Controlled Release doi:10.1016/j.jconrel.2011.01.014  Siqi Guo, Amy 
Donate, Guarav Basu, Cathryn Lundberg, Loree Heller, Richard Heller 
“Electro-gene transfer to the skin using a non-invasive multi-electrode 
array” with permission from Elsevier. 
 
Fig. 2 Plasmid expression and inflammation in the skin. 
Guinea pigs were treated as described in Methods 2.1 with pHBsAg.  
Expression of plasmid was evaluated at 48 hrs post treatment by IHC 
(A-IO; B I + EP).  Inflammation was measured 96 hrs post treatment 
and assessed by H&E (C-No treatment; D- IO, E – I + EP) at 100X 
magnification and 200X magnification (F- I + EP). 
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Fig. 3 Visual assessment of skin damage and healing. 
Guinea pigs were treated as described in Methods 2.1 with pHBsAg 
with or without EP.  Images were taken of skin pre treatment, 
immediately post treatment, and at 24, 48, 72, 96 hours and at 7 
days.  Arrows indicate the treatment sites. 
 
Fig. 4 Evaluation of anti-HBs serum titer. 
Guinea pigs were treated as described in Methods 2.1 with pHBsAg.  
Serum was collected at multiple time points and an ELISA performed. 
Geometric mean titers are expressed.  Positive was determined by two 
standard deviations greater than the Day 0 OD. IO and EP n=6 for 
each experiment with 3 independent experiments conducted (total 
n=18).  Statistics were determined by two-sided student t-test with 
bonferroni correction to p<0.05. 
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